

1 **Title:**

2 Lipid metabolism links nutrient-exercise timing to insulin sensitivity in men classified
3 as overweight or obese.

4

5 **Authors:**

6 Edinburgh, R.M.¹, Bradley, H.E.², Abdullah, N-F.^{2,3}, Robinson, S.L.², Chrzanowski-
7 Smith, O.J.¹, Walhin, J-P. ¹, Joannis S.²., Manolopoulos, K.N.⁴, Philp, A.⁵, Hengist,
8 A.¹, Chabowski, A.⁶, Brodsky, F.M.⁷ Koumanov, F.¹, Betts, J.A.¹, Thompson, D.¹,
9 Wallis, G. A.², Gonzalez, J.T.^{1,8}

10

11 **Author Contributions:**

12 RME, GAW and JTG designed the research; RME, HEB, N-FA, SLR, OJCS, JPW,
13 KM, AH, JB, GAW and JTG conducted the research, RME, HEB, N-FA, SLR, FK,
14 SJ, AP, AC, FMB and JTG analyzed the data, RME, N-FA and JTG performed the
15 statistical analysis, RME, GAW and JTG primarily wrote the paper, GAW was
16 responsible for the acute study and JTG was responsible for the training study and
17 all authors read and approved the final version of the manuscript.

18

19 **Author Affiliations:**

20 ¹Department for Health, University of Bath, Bath, United Kingdom

21 ²School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham,
22 Birmingham, United Kingdom

23 ³Department of Health Sciences, Faculty of Sport Sciences and Coaching, Universiti
24 Pendidikan Sultan Idris, Perak, Malaysia.

25 ⁴Institute of Metabolism and Systems Research, University of Birmingham,
26 Birmingham, United Kingdom

27 ⁵Diabetes & Metabolism Division, Garvan Institute of Medical Research, Sydney,
28 New South Wales, Australia.

29 ⁶Department of Physiology, Medical University of Bialystok, Bialystok, Poland

30 ⁷Division of Biosciences, University College London, London, United Kingdom.

31 ⁸Lead contact.

32

33 **Address for Correspondence:**

34 Dr Javier T. Gonzalez,

35 Department for Health, University of Bath, Bath, BA2 7AY, United Kingdom

36 Tel: 0(+44) 1225 38 5518; E-mail: J.T.Gonzalez@bath.ac.uk; Twitter:

37 @Gonzalez_JT

38

39 Dr Gareth A. Wallis,

40 School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham,

41 Edgbaston, B15 2TT, UK.

42 Tel: +44(0) 121 414 4129; Email: G.A.Wallis@bham.ac.uk; Twitter: @Gareth_Wallis

43

44 **Name and address for reprint requests:**

45 Dr Javier T. Gonzalez,

46 Department for Health, University of Bath, Bath, BA2 7AY, United Kingdom

47 Tel: 0(+44) 1225 38 5518; E-mail: J.T.Gonzalez@bath.ac.uk; Twitter:

48 @Gonzalez_JT

49

50 **Trial Registrations:** <https://clinicaltrials.gov/> (Numbers: NCT02744183;
51 NCT02397304)

52

53 **Running Title:** Breakfast, exercise and metabolic health

54

55 **Keywords:** Exercise; Glucose; Insulin sensitivity; Nutrition; Metabolism

56

57 **FUNDING**

58 This study was supported by The Physiological Society (UK) and the Allen

59 Foundation Inc. (USA), N-FA was supported by a PhD Scholarship from the Ministry

60 of Education, Malaysia. FK is funded by the Medical Research Council
61 (MR/P002927/1). FMB is funded by the Medical Research Council (MR/S008144/1).

62 **Abstract**

63 **Context:** Pre-exercise nutrient availability alters acute metabolic responses to
64 exercise, which could modulate training responsiveness. We hypothesised that in
65 men with overweight/obesity, acute exercise before *versus* after nutrient ingestion
66 would increase whole-body and intramuscular lipid utilization, translating into greater
67 increases in oral glucose insulin sensitivity over 6-weeks of training.

68 **Design and Participants:** We showed in men with overweight/obesity (mean±SD
69 for BMI: 30.2±3.5 kg·m⁻² for acute, crossover study, 30.9±4.5 kg·m⁻² for randomized,
70 controlled, training study) a single exercise bout before *versus* after nutrient
71 provision increased lipid utilisation at the whole-body level, but also in both type I
72 ($p<0.01$) and type II muscle fibres ($p=0.02$). We then used a 6-week training
73 intervention to show sustained, 2-fold increases in lipid utilisation with exercise
74 before *versus* after nutrient provision ($p<0.01$).

75 **Main Outcome Measures:** Postprandial glycemia was not differentially affected by
76 exercise training before vs after nutrient provision ($p>0.05$), yet plasma was reduced
77 with exercise training before, but not after nutrient provision ($p=0.03$), resulting in
78 increased oral glucose insulin sensitivity when training was performed before *versus*
79 after nutrient provision (25±38 vs -21±32 mL·min⁻¹·m⁻²; $p=0.01$) and this was
80 associated with increased lipid utilisation during exercise ($r=0.50$, $p=0.02$). Regular
81 exercise prior to nutrient provision augmented remodelling of skeletal muscle
82 phospholipids and protein content of the glucose transport protein GLUT4 ($p<0.05$).

83 **Conclusions:** Experiments investigating exercise training and metabolic health
84 should consider nutrient-exercise timing, and exercise performed before *versus* after
85 nutrient intake (i.e., in the fasted state) may exert beneficial effects on lipid utilisation
86 and reduce postprandial insulinemia.

87 **Précis**

88 Exercise in the fasted- *versus* fed-state increased intramuscular and whole-body
89 lipid use, translating into increased muscle adaptation and insulin sensitivity when
90 regularly performed over 6 weeks.

91 INTRODUCTION

92 Postprandial hyperinsulinemia and associated peripheral insulin resistance are key
93 drivers of metabolic diseases, such as type 2 diabetes (T2D) and cardiovascular
94 disease (1-3). Obesity and a sedentary lifestyle are independently associated with
95 changes in skeletal muscle that can reduce insulin sensitivity (4,5) and increase
96 hyperinsulinemia, contributing to elevated cardiovascular disease risk (2). Therefore,
97 increasing insulin sensitivity and reducing postprandial insulinemia are important
98 targets for interventions to reduce the risk of metabolic disease.

99

100 Regular exercise training represents a potent strategy to increase peripheral insulin
101 sensitivity and to reduce postprandial insulinemia (6). The beneficial effects of
102 exercise on oral glucose tolerance and insulin sensitivity can be attributed to both an
103 'acute phase' (during and straight after each bout of exercise performed) and the
104 more enduring molecular adaptations that accrue in response to regular exercise
105 (7). A single bout of endurance-type exercise activates contractile pathways in
106 exercising muscle, which (independently of insulin) translocate the glucose
107 transporter, GLUT4, to the plasma membrane and T-tubules to facilitate increased
108 transmembrane glucose transport (8-10). The mechanisms that underlie the
109 exercise-training induced increases in oral glucose insulin sensitivity include an
110 increase in the total amount of time spent in the 'acute phase' (7), but also other
111 adaptations that occur, such as changes in body composition (e.g. increased fat-free
112 mass and reduced adiposity), an increased mitochondrial oxidative capacity (11),
113 adaptations relating to glucose transport and insulin signaling pathways (12), and
114 alterations to the lipid composition of skeletal muscle (13,14).

115

116 Despite the potential for exercise to increase whole-body and peripheral insulin
117 sensitivity, there can be substantial variability in the insulin sensitizing effects of fully-
118 supervised exercise training programs (15). Crucially, this inter-individual variability
119 for postprandial insulinemia following exercise training has also been shown to be
120 greater than that of a control group (15), which demonstrates that some of this

121 variability to exercise is true inter-individual variability (16). Nutritional status and
122 thus the availability of metabolic substrates alters metabolism during and following
123 exercise (17-20). Carbohydrate feeding before and during exercise suppresses
124 whole-body and skeletal muscle lipid utilization (21,22) and blunts the skeletal
125 muscle mRNA expression of genes involved in exercise-adaptation for many hours
126 post-exercise (23-25). This raises the possibility that nutrient-exercise interactions
127 may regulate adaptive responses to exercise and thereby contribute to the apparent
128 individual variability in exercise responsiveness *via* skeletal muscle adaptation
129 and/or pathways relating to substrate metabolism.

130

131 Emerging data in lean, healthy men suggests that nutrient provision affects adaptive
132 responses to exercise training (26,27). However, feeding and fasting may exert
133 different physiological responses in people who are overweight or obese compared
134 to lean individuals, for example, extended morning fasting *versus* daily breakfast
135 consumption upregulates the expression of genes involved in lipid turnover in
136 adipose tissue in lean, but not in obese humans (28). Therefore, in order to fully
137 understand the potential for nutrient-exercise timings to alter metabolism, exercise-
138 adaptations and metabolic health in individuals at increased risk of metabolic
139 disease, there is a need to study the most relevant populations, such as individuals
140 classified as overweight or obese (29). It is currently unknown whether nutrient
141 provision before *versus* after exercise affects adaptations to exercise training in
142 these populations.

143

144 To this end, the aim of the present work was to assess the acute and chronic effects
145 of manipulating nutrient-exercise timing on lipid metabolism, skeletal muscle
146 adaptations, and oral glucose insulin sensitivity in men with overweight or obesity.
147 We hypothesized that nutrient-exercise interactions would affect the acute metabolic
148 responses to exercise, with increased whole-body and intramuscular lipid utilization
149 with exercise before *versus* after nutrient provision. We also hypothesized that these
150 acute responses to exercise before *versus* after nutrient provision would result in

151 greater training-induced increases in oral glucose insulin sensitivity in men classified
152 as overweight or obese.

153 MATERIALS AND METHODS

154 Ethical Approval

155 This project comprised two experiments. We first assessed the acute metabolic and
156 mRNA responses to manipulating nutrient-exercise timing (**Acute Study**), followed
157 by a 6-week randomized controlled trial to assess the longer-term (i.e. training)
158 adaptations in response to nutrient-exercise timing (**Training Study**). All participants
159 provided informed written consent prior to participation. Potential participants were
160 excluded if they had any condition, or were taking any medication, known to alter
161 any of the outcome measures. The studies were registered at <https://clinicaltrials.gov>
162 (NCT02397304 and NCT02744183, respectively). Protocols were approved by the
163 National Health Service Research Ethics Committee (15/WM/0128 & 16/SW/0260,
164 respectively) and experiments were conducted in accordance with the Declaration
165 of Helsinki.

166

167 Acute Study

168 In the **Acute Study**, 12 sedentary, men classified as overweight or obese were
169 recruited from the Birmingham region of the UK. The main exclusion criteria included
170 being regularly physically active, having hypertension or possible (undiagnosed)
171 T2D. Participant characteristics are shown in **Table 1**.

172

173 This was a randomised cross-over study where on one visit (breakfast-exercise or
174 BR-EX), a standardised breakfast (cornflake cereal with skimmed milk, wholemeal
175 toast, sunflower spread and strawberry jam) was consumed upon arrival at the
176 laboratory (and following 48 h of diet control). The breakfast provided 25% of
177 estimated daily energy requirements [calculated as resting metabolic rate (RMR)
178 multiplied by a physical activity factor of 1.53 (30)] and was 65% carbohydrate, 20%
179 fat and 15% protein. After a 90-min period of rest, 60 min of cycling exercise was
180 then performed at 65% peak oxygen uptake ($\dot{V}O_2$ peak). Expired gas samples were
181 collected at 25-30 min and 55-60 min of exercise to determine whole-body substrate
182 utilisation rates. Blood was sampled in the overnight-fasted state, at 45 min post

183 breakfast and immediately before exercise was performed (90 min post breakfast),
184 every 30 min during exercise and at 60 min intervals during a 3-h post-exercise
185 recovery. In a subset of participants ($n=8$) *vastus lateralis* muscle was sampled pre-
186 and immediately post-exercise to assess fiber-type specific intramuscular
187 triglyceride (IMTG) and mixed-muscle glycogen utilization. A third muscle sample
188 (taken at 3 h post-exercise) was used to assess the intramuscular gene expression
189 (mRNA) responses to exercise ($n=7$). On the other visit (exercise-breakfast or EX-
190 BR) the participants completed the same protocol, but the breakfast was consumed
191 immediately after the post-exercise muscle sample. The primary outcome for the
192 **Acute Study** was intramuscular lipid utilisation during exercise performed before
193 *versus* after nutrient ingestion.

194

195 **Training Study**

196 To assess longer-term adaptive (i.e. training) responses to altering nutrient-exercise
197 timing (**Training Study**) we recruited 30, overweight and obese, sedentary men
198 (self-reported non-exercisers) from the Bath region of the UK (**Table 1**). This was a
199 single-blind, randomized, controlled trial, with participants allocated to a no-exercise
200 control group (CON; $n=9$) a breakfast before exercise group (BR-EX; $n=12$) or an
201 exercise before breakfast group (EX-BR; $n=9$) for 6-weeks (**Figure 1**). The exercise
202 was supervised moderate-intensity cycling (Monark Exercise AB, Vansbro, Sweden)
203 performed 3 times per week, starting at 50% peak power output [PPO] (weeks 1-3)
204 and increasing to 55% PPO (weeks 4-6). The duration of the exercise sessions
205 progressed from 30- (week 1) to 40- (week 2) to 50-min (weeks 3-6). All sessions
206 were supervised at the University of Bath. During every one of the 336 exercise
207 training sessions, 1-min expired gas samples were collected every 10 min to assess
208 substrate utilization and heart rate (Polar Electro Oy, Kempele, Finland) and ratings
209 of perceived exertion (31) were recorded.

210

211 Participants ate their evening meal before 2000 h the evening prior to any exercise
212 sessions. Participants in BR-EX were given a drink in an opaque bottle made from

213 1.3 g carbohydrate·kg body mass⁻¹ maltodextrin (MyProtein, Northwich, UK) with
214 vanilla flavoring (20% carbohydrate solution) for consumption 2-h before exercise.
215 They were asked not to eat or drink anything else (except water *ad libitum*) in this
216 period and confirmed they had consumed the drink before exercising. After exercise,
217 they were provided a taste matched placebo (water and vanilla flavoring) to consume
218 2-h after exercise and were asked not to consume anything else during this period.
219 Participants in EX-BR were given the same drinks, but with the order of the drinks
220 reversed. Participants in CON were given the same drinks for three days per week
221 during the intervention, with the carbohydrate drink as breakfast (0800-0900 h) and
222 the placebo for consumption with their lunch (1100-1300 h). These participants were
223 asked not to consume anything else between the drinks. There were no other diet
224 controls in the intervention. Blinding of the groups was deemed successful, because
225 at exit interview, 25 participants (83%) revealed they could not detect a difference
226 between the carbohydrate and placebo drinks or could not identify which contained
227 carbohydrate. Five participants determined which drink had carbohydrate (CON $n=1$,
228 BR-EX $n=2$, EX-BR $n=1$), but this is within the proportion that could do so at random.
229

230 Pre- and post-intervention, an oral glucose tolerance test (OGTT), a *vastus lateralis*
231 muscle sample (fasting, rested state) and an exercise test (to assess $\dot{V}O_2$ peak and
232 the capacity for lipid utilization during exercise in the fasted-state) were undertaken.
233 Post-intervention tests were between 24 h to 48 h (for muscle sampling) and 48 h to
234 72 h (for OGTT) after the last exercise training session, to reduce any residual effects
235 of the last exercise bout performed on these measurements. The primary outcome
236 for the **Training Study** was the pre- to post-intervention change in the glycaemic
237 and insulinemic responses to the OGTT, which were also used to derive an index of
238 oral glucose insulin sensitivity (as described subsequently).

239

240 **Pre-trial standardizations**

241 For both studies, the participants were asked to maintain their normal physical
242 activity behaviors and to abstain from alcoholic and caffeinated drinks for 24 h prior

243 to all main laboratory trials. Food intake ceased at 2000 h \pm 1 h on the evening before
244 testing and participants fasted overnight (minimum of 10 h). For all trials, participants
245 arrived at the laboratory at 0800 \pm 1 h, with the exact time replicated for subsequent
246 trials. For the **Acute Study**, participants were provided with a standardized weight
247 maintaining diet (50% carbohydrate, 35% fat, 15% protein) based on their estimated
248 energy requirements (RMR multiplied by the physical activity factor of 1.53 as stated
249 previously) for consumption for 48 h prior to main trials. For the **Training Study**, they
250 recorded the composition of their evening meal on the day before a pre-intervention
251 trial and replicated this meal for the post-intervention trial, in line with guidelines for
252 testing postprandial glycemic control (32). We have shown that this protocol
253 produces fasting muscle and liver glycogen and fasting intramuscular lipid
254 concentrations that are consistent across trial days (33).

255

256 **Anthropometry**

257 Stature was measured to the nearest 0.1 cm using a stadiometer (Seca Ltd,
258 Birmingham, UK). Body mass was measured to the nearest 0.1 kg using electronic
259 weighing scales (**Acute Study**: Ohaus Champ II Scales, USA; **Training Study**:
260 BC543 Monitor, Tanita, Japan). Waist and hip circumferences were measured to the
261 nearest 0.1 cm and according to the World Health Organization guidelines.

262

263 **Exercise tests**

264 Participants completed exercise tests on an electronically-braked ergometer. In the
265 **Acute Study**, the starting intensity was 35 W, and this was increased by 35 W every
266 3 min until volitional exhaustion. In the **Training Study**, the starting intensity for the
267 exercise test was 50 W which was increased by 25 W every 3 min. Heart rate (Polar
268 Electro Oy, Kempele, Finland) and continuous breath-by-breath measurements
269 were recorded (**Acute Study**: Oxycon Pro, Jaeger, Wurzburg, Germany; **Training**
270 **Study**: TrueOne2400, ParvoMedics, Sandy, USA). Volume and gas analyzers were
271 calibrated using a 3-L calibration syringe (Hans Rudolph, Kansas City, USA) and a
272 calibration gas (16.04% O₂, 5.06% CO₂; BOC Industrial Gases, Linde AG,

273 Germany). Peak power output (PPO) was calculated as the work rate of the final
274 completed stage, plus the fraction of time in the final non-completed stage, multiplied
275 by the W increment. $\dot{V}O_2$ peak was the highest measured $\dot{V}O_2$ over a 30 s period,
276 using methods and attainment criteria previously reported (34).

277

278 **Blood sampling and analysis**

279 In the **Acute Study**, 10 mL blood was sampled from an antecubital forearm vein and
280 6 mL was dispensed into ethylenediaminetetraacetic acid-coated tubes (BD, Oxford,
281 UK) and centrifuged (4°C at 3500 rpm) for 15 min (Heraeus Biofuge Primo R, Kendro
282 Laboratory Products Plc., UK). Resultant plasma was dispensed into 0.5 mL aliquots
283 and frozen at -20°C, before longer-term storage at -80°C. A proportion of the sample
284 (4 mL) was allowed to clot in a plain vacutainer prior to centrifugation, for serum.
285 Samples were analyzed for plasma glucose, glycerol and NEFA using an ILAB 650
286 Clinical Chemistry Analyzer (Instrumentation Laboratory, Warrington, UK). Serum
287 insulin concentrations were measured with an ELISA kit (Invitrogen; Cat#KAQ1251)
288 and Biotek ELx800 analyzer (Biotek Instruments, Vermont, USA).

289

290 In the **Training Study**, prior to blood sampling participants placed their dominant
291 hand into a heated-air box set to 55°C. After 15 min of rest, a catheter was placed
292 (retrograde) into a dorsal hand vein and 10-mL of arterialized blood was drawn for a
293 baseline sample in the overnight-fasted state (35). Then a 75-g OGTT was
294 completed and arterialized blood sampled every 15 min for 2 h and processed (as
295 detailed above) for plasma. Plasma glucose (intra-assay CV: 2.50%), glycerol,
296 triglyceride (glycerol-blanked), and total- HDL- and LDL-cholesterol concentrations
297 were measured using an automated analyzer (Daytona; Randox Lab, Crumlin, UK).
298 Plasma insulin (Mercodia AB; reference #10-1113-01) and C-peptide (Sigma
299 Aldrich; reference #EZHCP-20K) concentrations were measured using commercially
300 available ELISA kits (intra-assay CV for insulin: 3.86% and for C-peptide: 4.26%).
301 Non-esterified fatty acid (NEFA) concentrations were assessed via an enzymatic
302 colorimetric kit (WAKO Diagnostics; references #999-34691/#991-34891; intra-

303 assay CV: 7.95%). All analysis was done in batch and for a given participant all
304 samples were included on the same plate.

305

306 **Muscle sampling**

307 All *vastus lateralis* skeletal muscle samples were collected under local anesthesia
308 (~ 5 mL 1% lidocaine, Hameln Pharmaceuticals Ltd., Brockworth, UK) and from a 3-
309 6-mm incision at the anterior aspect of the thigh using a 5-mm Bergstrom biopsy
310 needle technique adapted for suction. For the **Acute Study**, samples were collected
311 pre- and immediately post-exercise and at 3 h post-exercise. To enable the analysis
312 of the IMTG content ~ 15-20 mg of each sample was embedded in Tissue-Tek OCT
313 (Sigma Aldrich, Dorset, UK) on cork disc and frozen in liquid nitrogen cooled
314 isopentane, before being transferred into an aluminium cryotube and stored at -80°C.
315 Remaining muscle (for glycogen and gene expression analysis) was frozen in liquid
316 nitrogen and stored at -80°C. For the **Training Study**, samples were collected pre-
317 and post-intervention with participants in a fasted, resting state, with both samples
318 collected from their dominant leg. Muscle was extracted from the needle and frozen
319 in liquid nitrogen, before storage at -80 °C. Frozen wet muscle (80-100 mg) was
320 freeze-dried and powdered, with visible blood and connective tissue removed. Ice
321 cold lysis buffer (50 mM Tris [pH 7.4], 150 mM NaCl, 0.5% Sodium deoxycholate;
322 0.1% SDS and 0.1% NP-40) with protease and phosphatase inhibitors was added.
323 Samples were homogenized with a dounce homogenizer, before a 60 min incubation
324 (4°C with rotation) and 10 min centrifugation (4°C and 20,000 g). The protein content
325 of the resultant supernatant was measured using a bicinchoninic acid assay.

326

327 **Intramuscular triglyceride (Acute Study)**

328 The muscle mounted in Tissue-Tek was cut into 5 µm thick transverse sections with
329 a cryostat at -25°C (Bright 5040, Bright Instrument Company; Huntingdon, England)
330 and collected onto an uncoated glass slide and frozen immediately after sectioning.
331 Each slide had 4 samples for a participant (pre- and post-exercise both trials) to
332 decrease variation in staining intensity between muscle sections and slides were

333 prepared and analyzed for each participant. For analysis, cryosections were
334 removed from the freezer and fixed immediately in 3.7% formaldehyde for 60 min.
335 Slides were then rinsed with distilled water (3 x 30 s) and treated for 5 min with 0.5%
336 Triton-X100 in phosphate-buffered solution (PBS; 137 mmol·L⁻¹ sodium chloride, 3
337 mmol·L⁻¹ potassium chloride, 8 mmol·L⁻¹ sodium phosphate dibasic, 3 mmol·L⁻¹
338 potassium phosphate monobasic). The slides were washed (3 x 5 min in PBS) and
339 incubated for 2 h at room temperature with anti-myosin heavy chain I antibody
340 (MHCI; mouse IgM, Developmental Studies Hybridoma Bank: reference #A4.480)
341 and anti-dystrophin antibody (mouse IgG2b, Sigma Aldrich: reference #D8168) in
342 5% goat serum diluted in PBS (1:1 PBS dilution). This was followed by washes in
343 PBS (3 x 5 min), after which conjugated secondary antibodies [goat anti mouse
344 (GAM) IgM conjugated to AlexaFluor 633 for MHCI; Thermo Fisher: reference
345 #A21046; and GAM IgG2b conjugated to AlexaFluor 594 for dystrophin; Thermo
346 Fisher: reference #A21145] were added and incubated at room temperature (30 min)
347 followed by washes in PBS. Then, muscle sections were incubated in BODIPY
348 493/503 solution (Thermo Fisher: reference #D3922) for 20 min at room temperature
349 in a dark room before washes (2 x 3 min in PBS). Stained sections were embedded
350 in Mowiol 4-88 mounting medium (Fluka: reference #81381) and covered with a
351 coverslip. Slides were left to dry overnight at room temperature before analysis by
352 confocal microscope in duplicate (DMIRE2, Leica Microsystems; 40x oil objective;
353 1.25 NA). An argon laser 488 nm was used to excite BODIPY-493/503 (emission
354 510-652 nm), while a helium-neon 594 nm and 633 nm laser line were used to excite
355 Alexa Fluor 594 (dystrophin, emission 6680698 nm) and AlexaFluor 633 (MHCI,
356 emission 698-808 nm), respectively. Images were scanned in projection of 4 lines in
357 1024x1025 pixels format. Quantification of the lipid droplets was performed using
358 Image J software and the intramuscular triglyceride (IMTG) content of each sample
359 was calculated as the percent area of bodipy staining of the total fiber area ([BODIPY
360 stained area [μm²] / area of muscle [μm²]*100).

361

362 **Muscle glycogen (Acute Study)**

363 Muscle glycogen concentrations were measured using a method described
364 previously (36). Briefly, 10-15 mg of frozen tissue was powdered and transferred into
365 a glass tube pre-cooled on dry ice. Thereafter, the samples were hydrolyzed by
366 adding a 500 μ l of 2M HCL and then incubated for 2 h at 95 °C. After cooling to room
367 temperature, 500 μ l 2M NaOH was added. Samples were centrifuged and the
368 supernatant was analyzed for glucose concentrations using an ILAB 650 Clinical
369 Chemistry Analyzer (Instrumentation Laboratory, Warrington, UK).

370

371 **Gene expression (Acute Study)**

372 The mRNA expression of 34 metabolic genes was analyzed using a custom RT2
373 Profiler PCR Array (Qiagen, USA). First, RNA was extracted from 20-40 mg of
374 powdered muscle tissue using Tri reagent (1 mL, Sigma Aldrich, UK, T9424). After
375 addition of chloroform (200 μ L, Acros organics 268320025), tubes were incubated
376 at room temperature for 5 min and centrifuged for 10 min (4 °C at 12 000 g). The
377 RNA phase was mixed with an equal volume of ice cold 70% ethanol and RNA was
378 purified on Reliaprep spin columns (Promega, USA, Z6111) as per manufacturer's
379 instructions. The LVis function of the FLUOstar Omega microplate reader was used
380 to measure RNA concentrations to ensure all samples for each participant had the
381 same amount of RNA (184 ng - 400 ng) and samples were reverse transcribed to
382 cDNA using the RT2 First Strand kit (Qiagen, UK, 330401). Quantitative RT-PCR
383 analysis was performed using custom designed 384-well RT2 PCR Profiler Arrays
384 (Qiagen) and RT2 SYBR Green Mastermix (Qiagen) on a CFX384 Real-Time PCR
385 Detection system (BioRad). 2.8 ng cDNA was added to each well. All primers that
386 were used are commercially available (**Table 2**). The absence of genomic DNA, the
387 efficiency of reverse-transcription and the efficiency of the PCR assay were
388 assessed for each sample and conformed to manufacturer's limits. Relative mRNA
389 expression was determined via the $2^{-\Delta\Delta CT}$ method (37). Housekeeper genes (β actin
390 [Refseq# NM_001101]; ribosomal protein lateral stalk subunit P0 [Refseq#
391 NM_001002] and β -2-microglobulin [Refseq# NM_004048] were internal controls.

392

393 **Western blotting (Training Study)**

394 For western blots, 40 µg of protein was loaded for each sample and separated via
395 sodium dodecyl sulfate polyacrylamide gel electrophoresis on Tris-glycine SDS–
396 polyacrylamide gels (15% for OXPHOS and CPT-1, 10% CD36 and GLUT4 and 8%
397 for AMPK, CHC22, CHC17, Akt and AS160). Gels were electro-blotted (semi-dry
398 transfer) onto a nitrocellulose membrane and were then washed in Tris-buffered
399 saline (0.09% NaCl, 100 mM Tris–HCl pH 7.4) with 0.1% Tween 20 (TBS-T) and
400 incubated for 30 min in a blocking solution (5% non-fat milk in TBS-T). Membranes
401 were incubated overnight at 4 °C with primary antibodies against OXPHOS (Abcam:
402 reference #ab110411), CPT-1 (Abcam: reference #ab134988), CD36 (Abcam:
403 reference #ab133625), GLUT4 [self-raised rabbit polyclonal antibody against the C-
404 terminus of GLUT4 (38)], CHC22 [SHL-KS, affinity purified self-raised rabbit
405 polyclonal against the CHC22 C-terminus cross-absorbed against the CHC17 C-
406 terminus (39)], CHC17 [TD.1 self-raised mouse monoclonal against CHC17 terminal
407 domain (40)] AMPKα (Cell Signalling Technologies: reference #2532), Akt (Cell
408 Signaling Technologies: reference #3063), AS160 (Millipore: reference #07-741). It
409 should be noted that the AMPKα antibody recognises both α1 and AMPKα2 isoforms
410 of the catalytic subunit and does not detect the regulatory AMPKβ or AMPKγ subunits
411 (41). Following incubation with the primary antibodies, the membranes were washed
412 in TBS-T and incubated for 60 min in a 1:4000 dilution of anti-species IgG
413 horseradish peroxidase-conjugated secondary antibodies in the aforementioned
414 blocking solution. After further washes, membranes were incubated in an enhanced
415 chemiluminescence reagent and visualized (EpiChemi II Darkroom, UVP, Upland,
416 USA). The band densities were quantified using Image Studio Lite software (Version
417 5.2; LI-COR, Nebraska, USA) and were normalized to either GAPDH (Proteintech:
418 reference #60004-1-Ig) or Actin (Sigma Aldrich: reference #A2066), before the pre-
419 to post-intervention change was calculated. Pre- and post-intervention samples from
420 any given participant were included on the same gel. Citrate synthase activity was
421 measured using a commercially available assay (Abcam: reference #ab119692).

422

423 **Phospholipid composition (Training Study)**

424 Samples were freeze-dried, powdered under liquid nitrogen, and transferred into
425 glass tubes containing 2 ml of methanol and butylated hydroxytoluene (0.01%) and
426 heptadecanoic acid (as an internal standard), followed by the addition of 4 mL of
427 chloroform and 1.5 mL of water, before lipids were extracted. The lipid containing
428 fraction was transferred into thin-layer chromatography (TLC; Kieselgel 60, 0.22 mm,
429 Merck, Darmstadt, Germany) silica plates and lipids were separated by TLC with a
430 heptane: isopropyl ether: acetic acid (60:40:3, vol/vol/vol) resolving solution. Lipid
431 bands were made visible by spraying the plates with a 0.2% solution of 3'-
432 dichlorofluorescein in methanol and recognized under ultraviolet light using standards
433 on the plates. Then the gel bands containing phospholipids were scraped off the
434 plates, transferred into screw cap tubes and transmethylated with BF₃/methanol.
435 The fatty acid methyl esters (FAMES) were then dissolved in hexane and analyzed
436 by GLC. A Hewlett-Packard 5890 Series II gas chromatograph with Varian CP-SIL
437 capillary column (100 m, internal diameter of 0.25 mm) and flame-ionization detector
438 were used. In accordance with the retention times of standards, the individual long-
439 chain fatty acids quantification was performed. The content of phospholipids was
440 estimated as the sum of the total fatty acid species and expressed in nanomoles per
441 milligram of dry mass (42,43).

442

443 **Energy expenditure and intake (Training Study)**

444 Average daily energy expenditure was calculated as the sum of the resting metabolic
445 rate (RMR), diet-induced thermogenesis (10% of self-reported daily energy intake)
446 and physical activity energy expenditure (PAEE). To assess RMR, participants
447 rested in a semi-supine position for 15 min before 4 x 5-min expired air samples
448 were collected (44). The participants were provided with the mouthpiece 1 min prior
449 to sample collections (as a stabilization period) which were collected into a 200-L
450 Douglas bag (Hans Rudolph, Kansas City, USA) via falconia tubing (Baxter,
451 Woodhouse and Taylor Ltd, Macclesfield, UK). Concurrent measures of inspired air
452 were also made to correct for changes in the ambient O₂ and CO₂ concentrations.

453 Expired O₂ and CO₂ concentrations were measured in a volume of each sample
454 using paramagnetic and infrared transducers (Mini HF 5200, Servomex Group Ltd.,
455 Crowborough, UK). The sensor was calibrated with low (0% O₂ and 0% CO₂) and
456 high (16.04% O₂, 5.06% CO₂) calibration gases (BOC Industrial Gases, Munich,
457 Germany). Substrate utilization rates were then calculated via stoichiometric
458 equations (45,46). Energy expenditure was calculated assuming that fatty acids,
459 glucose and glycogen provide 40.81 kJ·g⁻¹, 15.64 kJ·g⁻¹ and 17.36 kJ·g⁻¹ of energy,
460 respectively. To measure free-living PAEE, participants wore an Actiheart™ monitor
461 over 7 days (Cambridge Neurotechnology, Papworth, UK). This monitor integrates
462 accelerometry and heart rate signals and has been validated as a measure of energy
463 expenditure (47-49). Energy expenditure and heart rate values from rest and
464 exercise were entered in the Actiheart™ software for an individually calibrated
465 model. Participants were also asked to keep a written record of their food and fluid
466 intake for 4 days over a typical 7-day period (including a weekend day) pre- and
467 during the last week of the intervention. Weighing scales were provided to increase
468 the accuracy of records. Records were analyzed using Nutritics software (Nutritics
469 Ltd., Dublin, Ireland). The macronutrient composition of each food was taken from
470 the manufacturer's labels, but if this was not possible (e.g. fresh products) foods
471 were analyzed via the software database or comparable brands were used to
472 provide the relevant information, and this was kept constant across records.

473

474 **Statistics**

475 In the **Acute Study**, the sample size was based upon data demonstrating an
476 attenuation of intramuscular lipid utilization during exercise with carbohydrate intake
477 before and during exercise with an effect size of $d = 1.5$. (22) We aimed to recruit 12
478 participants assuming at least 8 participants would complete the study with biopsies
479 to provide >90% power with α set at 0.05. In the **Training Study**, a sample size
480 estimation was completed using data from a training study in healthy, lean men (26).
481 In that study, a change in the plasma glucose AUC for an oral glucose tolerance test
482 (OGTT) of -65 ± 53 mmol·min·L⁻¹ was shown in an EX-BR group *versus* $+21 \pm 47$

483 mmol·min·L⁻¹ for a CON group. With α set at 0.05, 9 participants were required for a
484 >90% chance of detecting this effect. We therefore recruited 30 participants to
485 account for the possibility of an unequal allocation of participants across three
486 groups when using a stratified randomization schedule. Participants were allocated
487 to the CON ($n=9$), BR-EX ($n=12$) or EX-BR ($n=9$) groups using this schedule, which
488 was generated by JPW and included a factor for Physical Activity Level (PAL) and
489 the time-averaged glucose AUC for the baseline OGTT which was assessed using
490 a Freestyle Freedom Lite Glucose Meter. This was to ensure an even distribution of
491 less (PAL <1.65) and more active (PAL >1.65) participants and participants with
492 glucose AUC values above or below 8 mmol·L⁻¹.

493

494 Data are presented as means \pm 95% confidence intervals (CI), except for participant
495 characteristics (which are mean \pm SD). A Shapiro-Wilk test was performed to test for
496 normal distribution and if this was not obtained, non-parametric tests (e.g. Wilcoxon
497 matched-pairs signed rank tests) were employed. In the **Acute Study**, differences
498 between groups were assessed with paired t -tests or a two-way repeated measures
499 ANOVA (for variables dependent on time). In the **Training Study**, one-way ANOVAs
500 were used to assess differences between groups at baseline and two-way mixed-
501 design ANOVAs were used to assess differences between groups in response to the
502 intervention (group x time). If interaction effects were identified, independent t -tests
503 were used to locate variance, with Holm-Bonferroni step-wise adjustments made.
504 Correlations between variables were explored using Pearson r or Spearman R for
505 normal or non-normal distributions, respectively. A significance level of $p<0.05$ was
506 always used. The area under the concentration-time curve (AUC) was calculated via
507 the trapezoid rule and divided by the duration of an observation period of interest for
508 a time-averaged summary value. Plasma glucose and insulin concentrations were
509 used to assess oral glucose insulin sensitivity (the OGIS index) as per instructions
510 provided at; <http://webmet.pd.cnr.it/ogis/> (50). Statistical analyses were completed
511 on IBM SPSS statistics V 22 for windows (except for the Holm-Bonferroni
512 adjustments which were completed on Microsoft Excel) and Graph Pad Prism 7 was

513 used to prepare the figures. As we were unable to collect data from all participants
514 for all measured outcomes the n are always displayed in all figure and table captions.

515 **RESULTS**

516 **Exercise before nutrient ingestion increases whole-body and skeletal muscle**
517 **lipid utilization but does not differentially modulate muscle gene expression**

518 In the **Acute Study**, exercising before *versus* after nutrient provision increased the
519 acute plasma glucose and serum insulin responses to food consumption (**Figure 2A**
520 and **2B**). The plasma glucose AUC was 6.70 [6.00 to 7.39] mmol·L⁻¹·330 min⁻¹ with
521 exercise before nutrient provision *versus* 5.91 [5.33 to 6.50] mmol·L⁻¹·330 min⁻¹ with
522 exercise after nutrient provision ($p<0.01$). The serum insulin AUC was 86.9 [48.5 to
523 125.2] pmol·L⁻¹·330 min⁻¹ with exercise before nutrient provision *versus* 55.3 [31.2
524 to 79.3] pmol·L⁻¹·330 min⁻¹ with exercise after nutrient provision ($p<0.01$). Exercise
525 performed before *versus* after nutrient provision resulted in higher glycerol and non-
526 esterified fatty acid (NEFA) concentrations during the exercise (**Figure 2C** and **2D**).

527

528 Nutrient provision before exercise potently altered whole-body metabolism, resulting
529 in an increase in whole-body carbohydrate utilization (**Figure 2E**) and a decrease in
530 whole-body lipid utilization (**Figure 2F**). In skeletal muscle, glycogen utilization
531 during exercise (time effect, $p<0.01$) was independent of nutrient-exercise timing
532 (time x trial interaction effect $p=0.12$; **Figure 2G**). However, the type I muscle fibre
533 intramuscular triglyceride (IMTG) content was only reduced with exercise performed
534 before nutrient provision (time x trial interaction: $p=0.02$; **Figure 2H** and **2J**). A
535 similar pattern was observed for the type II muscle fibre IMTG content (time x trial
536 interaction: $p=0.04$; **Figure 2I** and **2J**), although the reduction with exercise before
537 nutrient provision did not achieve statistical significance after post-hoc corrections.
538 Nonetheless, clear differences (both $p<0.05$) in the net changes in the IMTG content
539 were observed in both fibre types with exercise before *versus* after nutrient provision
540 (for type I: -3.44 [-1.61 to -5.26]% *versus* 1.44 [-1.46 to 4.34]% area covered by lipid
541 staining and type II: -1.89 [-0.16 to -3.61]% *versus* 1.83 [0.50 to 3.17]% area covered
542 by lipid staining for exercise before *versus* after nutrient provision, respectively).

543

544 Of the 34 selected genes that are implicated in metabolic adaptations to exercise,
545 only 8 genes were altered by exercise, whereby *IRS-1* and *FATP1* were decreased
546 post-exercise compared to baseline ($p<0.05$) and *IRS-2*, *PDK4*, *PGC1 α* , *FATP4* and
547 *ACSL1* were increased post-exercise compared to baseline (all $p<0.05$). However,
548 only *PPAR δ* was differentially expressed by nutrient-exercise timing and was higher
549 with breakfast before *versus* after exercise ($p<0.05$; **Figure 3**).

550

551 **Exercise training before nutrient provision leads to sustained increases in** 552 **lipid utilization**

553 In the **Training Study** the compliance to the training was 100%, as all sessions were
554 completed as prescribed. The average exercise intensity was $62 \pm 5\%$ $\dot{V}O_2$ peak in
555 BR-EX and $62 \pm 4\%$ $\dot{V}O_2$ peak in EX-BR ($p=0.98$) and the heart rate (HR) response
556 and average rating of perceived exertion (RPE) to the exercise training were $140 \pm$
557 13 *versus* 134 ± 8 beats \cdot min $^{-1}$ in BR-EX *versus* EX-BR ($p=0.18$) and 13 ± 1 au *versus*
558 13 ± 1 au (6-20 rating scale) in BR-EX *versus* EX-BR; ($p=0.54$), respectively.

559

560 In the **Training Study** rates of whole-body lipid utilization were around 2-fold higher
561 with exercise before *versus* after nutrient provision and this difference between the
562 conditions was sustained throughout the whole 6-week intervention (**Figure 4A**). As
563 a consequence, regular exercise before (*versus* after) nutrient provision increased
564 cumulative whole-body lipid utilization (during exercise) over a 6-week intervention,
565 from 799 kcal [530 to 1069] in BR-EX to 1666 kcal [1260 to 2072] in EX-BR ($p<0.01$).
566 This was accompanied by a decrease in rates of whole-body carbohydrate utilization
567 during exercise (**Figure 5A**), as reflected by a decrease in the respiratory exchange
568 ratio (group effect, $p<0.01$; **Figure 5B**). However, cumulative energy expenditure
569 throughout the exercise intervention did not differ with exercise performed before
570 *versus* after nutrient provision (**Figure 5C**; 7207 [6739 to 7676] kcal in BR-EX *versus*
571 6951 [6267 to 7635] kcal in EX-BR; $p=0.48$).

572

573 **Exercise training before *versus* after nutrient provision increases an index of**
574 **oral glucose insulin sensitivity**

575 The oral glucose tolerance test-derived estimate of peripheral insulin sensitivity (the
576 OGIS index; $p=0.26$), postprandial glycaemia ($p=0.80$) and postprandial insulinemia
577 ($p=0.30$) were similar between groups pre-intervention (**Table 3**). The intervention-
578 induced changes in postprandial glycaemia (time x group interaction, $p=0.54$; **Figure**
579 **4B**) and fasting blood lipid profiles were unaffected by nutrient-exercise timing (pre-
580 and post-intervention data are shown in **Tables 3 and 4**). However, exercise training
581 before, but not after nutrient intake reduced postprandial insulinemia (time x group
582 interaction $p=0.03$; **Figure 4C**). Exercise training before *versus* after nutrient
583 provision also increased the OGIS index (time x group interaction $p=0.03$; **Figure**
584 **4D** with pre- and post-intervention data in **Table 3**). The plasma C-peptide-to-insulin
585 ratio was not differentially altered by nutrient-exercise timing (time x group
586 interaction, $p=0.12$; **Figure 4E**). The change in the OGIS index in response to
587 exercise training was positively and moderately correlated with cumulative lipid
588 utilization during exercise throughout the intervention (**Figure 4F**) but not with
589 cumulative energy expenditure (**Figure 5C**).

590 **Nutrient-exercise timing does not differentially alter body composition or**
591 **oxidative capacity**

592 Exercise before *versus* after nutrient provision resulted in comparable changes in
593 body mass (time x group interaction, $p=0.97$; **Figure 6A**), a marker of central
594 adiposity (the waist to hip ratio; time x group interaction, $p=0.17$, **Figure 6B**), and
595 the peak capacity for whole-body lipid utilization (time x group interaction, $p=0.14$;
596 **Figure 6C**). Exercise training increased $\dot{V}O_2$ peak by $\sim 3 \text{ mL}\cdot\text{kg}\cdot\text{min}^{-1}$ relative to a
597 no-exercise control (CON) group (time x group interaction, $p=0.01$) but the
598 magnitude of this increase in cardiorespiratory fitness was unaffected by nutrient
599 exercise timing ($p=0.54$ with breakfast-exercise *versus* exercise-breakfast). Self-
600 reported daily energy intake was unaffected by exercise or nutrient-exercise timing
601 (time x group interaction, $p=0.38$; **Table 5**), and although daily energy expenditure
602 was increased in the exercise groups *versus* control group (time x group interaction,
603 $p=0.01$; **Table 5**), this increase was unaffected by nutrient-exercise timing ($p=0.38$).

604 **Exercise training before nutrient provision increases phospholipid remodeling**

605 There was a significant effect on global skeletal muscle remodeling with exercise
606 before *versus* after nutrient ingestion as quantified by the sum of changes in the fatty
607 acid content of all phospholipid species ($p=0.01$; **Figure 7A**). Nutrient provision prior
608 to exercise prevented this exercise-induced increase in skeletal muscle phospholipid
609 remodeling as the sum of changes was not different to a non-exercise control group
610 ($p=0.41$). No clear time x group interaction effects were determined for any of the
611 measured fatty acid species, except for the proportion of 18:0, which increased with
612 exercise before nutrient provision compared to the control group (**Table 6**). The
613 change in the overall saturated fatty acid content of skeletal muscle phospholipids
614 was moderately and positively correlated with changes in postprandial insulinemia
615 and the relationship was robust to the exclusion of any single data point (**Figure 7B**).

616

617 **Exercise training before nutrient provision augments intramuscular**
618 **adaptations**

619 Skeletal muscle AMPK protein levels increased ~3-fold with exercise training
620 performed before- but not after-nutrient provision *versus* a no-exercise control group
621 (**Figure 8A**). However, these increases did not translate into differential changes in
622 proteins including CD36 and CPT-1 which are involved in fatty acid transport in
623 skeletal muscle [both $p>0.05$; data available online (51)], or markers of mitochondrial
624 oxidative capacity, including the protein levels of the OXPHOS complexes [all
625 $p>0.05$; data available online (51)] or citrate synthase activity (change from baseline:
626 $-2.1 \mu\text{mol}\cdot\text{min}^{-1}\cdot\text{mg of protein}^{-1}$ [-12.9 to 8.7] in CON, $7.6 \mu\text{mol}\cdot\text{min}^{-1}\cdot\text{mg of protein}^{-1}$
627 [-1.2 to 16.4] in BR-EX and $6.5 \mu\text{mol}\cdot\text{min}^{-1}\cdot\text{mg of protein}^{-1}$ [0.2 to 12.8] in EX-BR;
628 $p>0.05$). There were also no differential changes in the content of insulin signaling
629 proteins such as Akt2 or AS160 in response to nutrient-exercise timing ($p>0.05$;
630 **Figure 8B**). However, there was a ~2-fold increase in skeletal muscle GLUT4 protein
631 levels with exercise training performed before ($p=0.04$), but not after nutrient
632 provision ($p=0.58$) *versus* a non-exercise control group (**Figure 8A**). There was also
633 an increase in the protein levels of the CHC22 clathrin isoform and its associated

634 adaptor protein (GGA2) relative to the CHC17 clathrin isoform, with exercise before
635 *versus* after nutrient provision (both $p < 0.05$; **Figure 8B**). When we examined the
636 CHC22 isoform alone [data not shown but available online (51)] we noted baseline
637 differences which may have confounded the interpretation of these fold-changes due
638 to regression to the mean. We thus present the CHC22/CHC17 ratio (**Figure 8B**) to
639 reflect GLUT4-associated clathrin-mediated membrane traffic relative to total
640 clathrin-mediated membrane traffic.

641

642 **DISCUSSION**

643 This is the first study to investigate the effect of nutrient-exercise interactions on key
644 aspects of metabolic health in people classified as overweight or obese. We found
645 that a single exercise bout performed before, but not after, nutrient provision
646 increased whole body and skeletal muscle lipid utilization. We then used a 6-week
647 training program to reveal sustained, 2-fold increases in lipid utilization that were
648 maintained throughout 6 weeks of exercise training performed before *versus* after
649 nutrient provision. An oral glucose tolerance test-derived estimate of peripheral
650 insulin sensitivity (the OGIS index) increased with exercise training before *versus*
651 after nutrient provision and this was associated with increased lipid utilization during
652 the exercise training intervention. Exercise training prior to nutrient provision also
653 augmented remodeling of phospholipids and increased the levels of energy sensing
654 (i.e. AMPK) and glucose transport proteins (i.e. GLUT4) in exercised skeletal
655 muscle. These results indicate that nutrient-exercise timing modulates training
656 responsiveness in overweight men and link lipid utilization during exercise to
657 exercise-training-induced changes in aspects of metabolic health.

658

659 First, we showed that a single bout of exercise performed before *versus* after nutrient
660 intake increased whole-body lipid utilization. A blunting of intramuscular triglyceride
661 (IMTG) utilization has been shown in type I fibers of lean, healthy men in response
662 to carbohydrate ingestion before and during exercise, compared to exercise in the
663 fasted-state (22). Here, we demonstrated for the first time that exercise before

664 *versus* after breakfast consumption increases net IMTG utilization in men classified
665 as overweight or obese. Whilst the authors do acknowledge that absolute IMTG
666 content may have been underestimated due to the analytical procedures used to
667 estimate IMTG (i.e. use of Triton-X100 detergent, overnight drying of mounting
668 medium), all samples were treated consistently. We also showed that net skeletal
669 muscle glycogen utilization and acute skeletal muscle mRNA responses were largely
670 unaffected by the same exercise performed before *versus* after breakfast. This is
671 important, because muscle glycogen availability can alter muscle adaptations to
672 training (27). Lower muscle glycogen concentrations are therefore unlikely to have
673 driven the training responses we observed in the training study with the present
674 method of nutrient-exercise timing.

675

676 Altering substrate availability can also drive adaptive responses to exercise partly by
677 modulating acute mRNA expression in exercised skeletal muscle (52). However, in
678 the present study, only one measured gene was differentially expressed in response
679 to exercise before *versus* after nutrient provision. Specifically, we observed less of
680 an exercise-induced increase in skeletal muscle *PPAR* δ expression with exercise
681 before *versus* after nutrient provision, which is surprising given that *PPAR* δ has been
682 implicated in adaptations relating to oxidative capacity and lipid utilization (53).
683 However, previous research has also shown no differential increase in *PPAR* δ
684 expression in skeletal muscle when exercise was performed with carbohydrate
685 consumption before and during exercise *versus* in the fasted state (54). The different
686 response observed in the present study might be because we assessed the effect
687 of nutrient-exercise timing (i.e. nutrient provision before *versus* after exercise) rather
688 than the omission *versus* ingestion of nutrients. This suggests that inferences cannot
689 necessarily be extrapolated from studies assessing the effects of nutrient ingestion
690 *versus* nutrient omission, to inform responses to models of nutrient-exercise *timing*.

691

692 In the training study, we then showed that the acute increases in whole-body lipid
693 utilization during a single bout of exercise performed before *versus* after nutrient

694 intake were sustained throughout 6-weeks of exercise training. Moreover, only
695 exercise training performed before nutrient intake reduced postprandial insulinemia
696 and increased the oral glucose tolerance test-derived estimate of peripheral insulin
697 sensitivity (i.e. the OGIS index). As the plasma C-peptide-to-insulin ratio was not
698 differentially altered by nutrient-exercise timing, the reduction in postprandial
699 insulinemia with exercise performed before *versus* after nutrient ingestion is likely to
700 be due to a reduction in insulin secretion rather than an increase in hepatic insulin
701 extraction (55). It should also be noted that difference between the exercise groups
702 for the change in the OGIS index was also broadly equivalent to the difference
703 between individuals classified as having a healthy phenotype compared to
704 individuals with impaired glucose tolerance (56).

705

706 Exercise training before *versus* after nutrient provision also resulted in augmented
707 phospholipid remodeling in skeletal muscle. Moreover, the change in the saturated
708 fatty acid content of skeletal muscle phospholipids with exercise correlated with the
709 change in postprandial insulinemia. This supports prior observations that a higher
710 proportion of saturated fatty acids in skeletal muscle phospholipids negatively
711 correlates with insulin sensitivity (57). Single-leg exercise training has been used to
712 show increased polyunsaturated fatty acid content of skeletal muscle phospholipids
713 in an exercised *versus* non-exercised leg (58). Since that change was independent
714 of dietary intake, the reduction in the saturated fatty content of phospholipids was
715 likely due to a preferential upregulation of saturated fatty acid oxidation as a result
716 of the higher energy expenditure (59,60). However, because this previous work
717 involved changes in energy expenditure across experimental conditions, the role of
718 lipid utilization independent of energy expenditure on phospholipid remodeling could
719 not be explored. Here, we showed that skeletal muscle remodeling was increased
720 with exercise performed before *versus* after nutrient provision, presumably due to
721 increased lipid utilization in that condition.

722

723 AMPK is also nutrient sensitive and contributes to regulation of fatty acid utilization
724 (61), mitochondrial biogenesis (62) and the expression of proteins involved in
725 skeletal muscle glucose uptake, including GLUT4 and AS160 (63-65), which are key
726 players in whole-body insulin sensitivity (66). We observed greater increases in the
727 protein content of AMPK in skeletal muscle with exercise training before *versus* after
728 nutrient intake. The increase in the GLUT4 content of skeletal muscle we observed
729 with exercise before nutrient provision may be explained by this heightened AMPK
730 response and, in turn, may have contributed to increases in the OGIS index following
731 exercise training before *versus* after nutrient provision (67). Skeletal muscle AMPK
732 can be activated by increased fatty acid availability, independent of muscle glycogen
733 and AMP concentrations (68). Muscle glycogen utilization can modulate *AMPK* and
734 *GLUT4* mRNA expression with different exercise models (66). However, since we
735 observed no difference in muscle glycogen utilization with altered nutrient-exercising
736 timing in the acute study, the change in the GLUT4 content with exercise training
737 before *versus* after breakfast is likely to be attributable to repeated increases in fatty
738 acid availability, potentially through increases in the skeletal muscle AMPK content.
739 The AMPK antibody we used detects both isoforms of the catalytic subunits of AMPK
740 ($AMPK\alpha1$ and $\alpha2$). In human skeletal muscle, three different complexes have been
741 described [$\alpha2\beta2\gamma1$, $\alpha2\beta2\gamma3$, and $\alpha1\beta2\gamma1$; (69)] and our antibody therefore captured
742 all complexes. Accordingly, we cannot speculate whether a specific heterotrimeric
743 AMPK complex is predominately contributing to the increase in AMPK content that
744 we report. As such, the effect of nutrient-exercise timing on AMPK activation
745 warrants continued investigation.

746

747 The correct targeting and sequestration of GLUT4 into its intracellular insulin-
748 responsive compartments is also important for insulin sensitivity in skeletal muscle
749 (70,71). Clathrin heavy chain isoform 22 (CHC22) plays a specialized role in
750 regulating GLUT4 sequestration in human skeletal muscle (72), protecting GLUT4
751 from degradation (73) and making it more available for insulin-stimulated release.
752 We showed an increase in CHC22 protein levels in exercised muscle (relative to the

753 exercise effects on CHC17 protein levels) with exercise before *versus* after nutrient
754 provision. As the cognate clathrin CHC17 plays a widespread membrane traffic role
755 in many tissues, CHC17 levels provide a benchmark for general membrane traffic
756 changes compared to those in the GLUT4 pathway (74). The relative increase in
757 CHC22 levels we observed thus suggests that exercise before nutrient provision not
758 only augments GLUT4 protein levels, but potentially also the machinery necessary
759 for the appropriate sequestration and targeting of GLUT4 to its insulin-responsive
760 compartment. This may lead to improved GLUT4 translocation and contribute to the
761 increases in the OGIS index we observed with exercise training before *versus* after
762 nutrient intake. However, the CHC22 results reported here should be interpreted
763 cautiously due to the relatively small sample size and variability in the individual
764 CHC22 responses. Further work is therefore needed to investigate nutrient-exercise
765 interactions and their effect on CHC22 levels. In addition, the remodeling of skeletal
766 muscle phospholipids could have contributed to the ability of GLUT4 to fuse to the
767 muscle-plasma membrane via less rigid arrays of phospholipid molecules in plasma
768 membranes (75).

769

770 The greater increase in AMPK content we observed with exercise before nutrient
771 provision did not further augment measured markers of mitochondrial biogenesis in
772 skeletal muscle in response to exercise training in overweight men. This is in contrast
773 to prior work demonstrating that carbohydrate ingestion before and during exercise
774 suppresses exercise-induced increases in the content of proteins in skeletal muscle
775 involved in fatty acid transport and oxidation (26). This further highlights that the
776 model of nutrient-exercise timing that we employed (breakfast consumption before
777 *versus* after exercise) might be distinct from other types of nutrient timing. Although
778 changes in skeletal muscle mitochondrial content and/or oxidative capacity may be
779 involved in regulating insulin sensitivity (76), the lack of differential response with
780 exercise before *versus* after nutrition provision in this study suggests that these
781 factors are unlikely to explain the changes in the OGIS index with the current model
782 of nutrient-exercise timing employed (i.e. exercise before versus after breakfast). It

783 is also interesting that the intramuscular adaptations and changes in the OGIS index
784 that we observed occurred in the presence of similar changes in body composition,
785 self-reported daily dietary intake and total daily energy expenditure with altered
786 nutrient-exercise timing. Notwithstanding other factors that may have contributed to
787 the increases in oral glucose insulin sensitivity with exercise before *versus* after
788 nutrient ingestion, this highlights lipid metabolism as a potentially important
789 mechanism explaining the improvement in OGIS with regular exercise performed
790 before *versus* after breakfast.

791

792 It should also be noted that the responses observed for OGIS were an interaction
793 between groups, and thus the response to exercise before nutrient provision is an
794 increase relative to the non-exercise control group and the exercise after nutrient
795 intake group. Accordingly, these data may be specific to high-carbohydrate provision
796 and although this is typical of breakfasts in developed countries, it remains to be
797 seen whether lower-carbohydrate meals produce similar effects. Potential limitations
798 in our work also include the absence of a non-exercise fasting group, which would
799 have allowed us to explore the role of extended morning fasting *per se* in the training
800 study. However, our prior work has already shown that extended morning fasting in
801 an absence of exercise may impair insulin sensitivity and increase postprandial
802 insulinemia in obese humans (77).

803

804 To summarize, the present data are the first to show that exercise training before
805 *versus* after carbohydrate (i.e. breakfast) consumption affects responsiveness to
806 exercise training in men classified as overweight or obese, including greater
807 remodeling of skeletal muscle phospholipids, adaptations of proteins involved in
808 nutrient sensing and glucose transport in skeletal muscle, and increases in and index
809 of oral glucose insulin sensitivity. These data suggest that exercising in a fasted state
810 can augment the adaptive response to exercise, without the need to increase the
811 volume, intensity, or perception of effort of exercise. These responses may be linked
812 to the acute increases in lipid utilization during every bout of exercise performed in

813 the fasted- *versus* the fed-state (a difference that is sustained throughout a period of
814 training over 6-weeks). These findings therefore have implications for future
815 research and clinical practice. For example, exercise training studies should account
816 for nutrient-exercise timing if aspects of metabolic control are an outcome measure.
817 Secondly, to increase lipid utilization and oral glucose insulin sensitivity with training,
818 endurance-type exercise should be performed before *versus* after nutrient intake
819 (i.e. in the fasted state).

820

821 **ADDITIONAL INFORMATION**

822

823 **Data Availability**

824 Raw data are available as online supporting information
825 (<https://researchportal.bath.ac.uk/en/datasets/>).

826

827 **Competing interests**

828 None of the authors declare any conflicts of interest in relation to this work.

829

830 **Acknowledgments**

831 The authors thank Russell Davies, Esther Punter, Emily Fallon, Josh Dominy and
832 Lauren Davey for assisting and supervising some of the exercise training sessions,
833 Marine Camus for technical advice on Western blotting and Laura Wood for assisting
834 with Western blotting. We also thank all those who participated in the studies for their
835 time and commitment.

836 REFERENCES

- 837 1. DeFronzo RA, Gunnarsson R, Björkman O, Olsson M, Wahren J. Effects of
838 insulin on peripheral and splanchnic glucose metabolism in noninsulin-
839 dependent (type II) diabetes mellitus. *Journal of Clinical Investigation*.
840 1985;76(1):149-155.
- 841 2. Reaven GM. Role of insulin resistance in human disease. *Diabetes*.
842 1988;37(12):1595-1607.
- 843 3. Tricò D, Natali A, Arslanian S, Mari A, Ferrannini E. Identification,
844 pathophysiology, and clinical implications of primary insulin hypersecretion
845 in nondiabetic adults and adolescents. *JCI Insight*. 2018;3(24):Epub: doi:
846 10.1172/jci.insight.124912.
- 847 4. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The
848 disease burden associated with overweight and obesity. *JAMA*.
849 1999;282(16):1523-1529.
- 850 5. McLaughlin T, Lamendola C, Liu A, Abbasi F. Preferential fat deposition in
851 subcutaneous versus visceral depots is associated with insulin sensitivity.
852 *The Journal of Clinical Endocrinology & Metabolism*. 2011;96(11):E1756-
853 E1760.
- 854 6. Borghouts L, Keizer H. Exercise and insulin sensitivity: a review.
855 *International Journal of Sports Medicine*. 2000;21(1):1-12.
- 856 7. Sylow L, Richter EA. Current advances in our understanding of exercise as
857 medicine in metabolic disease. *Current Opinion in Physiology*. 2019;Epub:
858 <https://doi.org/10.1016/j.cophys.2019.04.008>.
- 859 8. Lund S, Pryor PR, Ostergaard S, Schmitz O, Pedersen O, Holman GD.
860 Evidence against protein kinase B as a mediator of contraction-induced
861 glucose transport and GLUT4 translocation in rat skeletal muscle. *FEBS*
862 *Lett*. 1998;425(3):472-474.
- 863 9. Geiger PC, Han DH, Wright DC, Holloszy JO. How muscle insulin sensitivity
864 is regulated: testing of a hypothesis. *Am J Physiol Endocrinol Metab*.
865 2006;291(6):E1258-1263.
- 866 10. Hansen PA, Wang W, Marshall BA, Holloszy JO, Mueckler M. Dissociation
867 of GLUT4 translocation and insulin-stimulated glucose transport in
868 transgenic mice overexpressing GLUT1 in skeletal muscle. *J Biol Chem*.
869 1998;273(29):18173-18179.
- 870 11. Holloszy JO, Coyle EF. Adaptations of skeletal muscle to endurance
871 exercise and their metabolic consequences. *Journal of Applied Physiology*.
872 1984;56(4):831-838.
- 873 12. O'Gorman DJ, Karlsson HK, McQuaid S, Yousif O, Rahman Y, Gasparro D,
874 Glund S, Chibalin AV, Zierath JR, Nolan JJ. Exercise training increases
875 insulin-stimulated glucose disposal and GLUT4 (SLC2A4) protein content in
876 patients with type 2 diabetes. *Diabetologia*. 2006;49(12):2983-2992.
- 877 13. Andersson A, Sjödin A, Olsson R, Vessby B. Effects of physical exercise on
878 phospholipid fatty acid composition in skeletal muscle. *American Journal of*
879 *Physiology-Endocrinology and Metabolism*. 1998;274(3):432-438.

- 880 14. Helge JW, Dela F. Effect of training on muscle triacylglycerol and structural
881 lipids: a relation to insulin sensitivity? *Diabetes*. 2003;52(8):1881-1887.
- 882 15. de Lannoy L, Clarke J, Stotz PJ, Ross R. Effects of intensity and amount of
883 exercise on measures of insulin and glucose: Analysis of inter-individual
884 variability. *PloS one*. 2017;12(5):e0177095.
- 885 16. Atkinson G, Batterham AM. True and false interindividual differences in the
886 physiological response to an intervention. *Experimental physiology*.
887 2015;100(6):577-588.
- 888 17. Chen Y-C, Travers RL, Walhin J-P, Gonzalez JT, Koumanov F, Betts JA,
889 Thompson D. Feeding influences adipose tissue responses to exercise in
890 overweight men. *American Journal of Physiology-Endocrinology and*
891 *Metabolism*. 2017;313(1):84-93.
- 892 18. Edinburgh RM, Hengist A, Smith HA, Travers RL, Koumanov F, Betts JA,
893 Thompson D, Walhin J-P, Wallis GA, Hamilton DL, Stevenson EJ, Tipton
894 KD, Gonzalez J. Pre-Exercise Breakfast Ingestion versus Extended
895 Overnight Fasting Increases Postprandial Glucose Flux after Exercise in
896 Healthy Men. *American Journal of Physiology-Endocrinology and*
897 *Metabolism*. 2018;315(5):1062-1074.
- 898 19. Gonzalez JT, Veasey RC, Rumbold PL, Stevenson EJ. Breakfast and
899 exercise contingently affect postprandial metabolism and energy balance in
900 physically active males. *British Journal of Nutrition*. 2013;110(4):721-732.
- 901 20. Wallis GA, Gonzalez JT. Is exercise best served on an empty stomach?
902 *Proc Nutr Soc*. 2019;78(1):110-117.
- 903 21. Edinburgh RM, Hengist A, Smith HA, Travers RL, Koumanov F, Betts JA,
904 Thompson D, Walhin JP, Wallis GA, Hamilton DL, Stevenson EJ, Tipton KD,
905 Gonzalez JT. Pre-exercise breakfast ingestion versus extended overnight
906 fasting increases postprandial glucose flux after exercise in healthy men.
907 2018;Accepted-ahead-of-print.
- 908 22. De Bock K, Richter EA, Russell A, Eijnde BO, Derave W, Ramaekers M,
909 Koninckx E, Leger B, Verhaeghe J, Hespel P. Exercise in the fasted state
910 facilitates fibre type-specific intramyocellular lipid breakdown and stimulates
911 glycogen resynthesis in humans. *The Journal of Physiology*.
912 2005;564(2):649-660.
- 913 23. Cluberton LJ, McGee SL, Murphy RM, Hargreaves M. Effect of
914 carbohydrate ingestion on exercise-induced alterations in metabolic gene
915 expression. *Journal of Applied Physiology*. 2005;99(4):1359-1363.
- 916 24. Civitarese AE, Hesselink MK, Russell AP, Ravussin E, Schrauwen P.
917 Glucose ingestion during exercise blunts exercise-induced gene expression
918 of skeletal muscle fat oxidative genes. *American Journal of Physiology-*
919 *Endocrinology and Metabolism*. 2005;289(6):1023-1029.
- 920 25. Stocks B, Dent JR, Ogden HB, Zemp M, Philp A. Postexercise skeletal
921 muscle signaling responses to moderate-to high-intensity steady-state
922 exercise in the fed or fasted state. *American Journal of Physiology-*
923 *Endocrinology and Metabolism*. 2018;316(2):230-238.

- 924 26. Van Proeyen K, Szulc K, Nielens H, Pelgrim K, Deldicque L, Hesselink M,
925 Van Veldhoven PP, Hespel P. Training in the fasted state improves glucose
926 tolerance during fat-rich diet. *The Journal of Physiology*. 2010;588(21):4289-
927 4302.
- 928 27. Burke LM, Hawley JA. Swifter, higher, stronger: What's on the menu?
929 *Science*. 2018;362(6416):781-787.
- 930 28. Gonzalez JT, Richardson JD, Chowdhury EA, Koumanov F, Holman GD,
931 Cooper S, Thompson D, Tsintzas K, Betts JA. Molecular adaptations of
932 adipose tissue to 6 weeks of morning fasting vs. daily breakfast
933 consumption in lean and obese adults. *The Journal of Physiology*.
934 2018;596(4):609-622.
- 935 29. Wallis GA, Gonzalez JT. Is exercise best served on an empty stomach?
936 *Proceedings of the Nutrition Society*. 2018;78(1):110-117.
- 937 30. FAO. Human energy requirements. Report of a Joint FAO/WHO/UNU
938 Expert Consultation, Rome, 17-24 October 2001.
939 <http://www.fao.org/3/y5686e/y5686e07htm#bm073>. 2004.
- 940 31. Borg G. Perceived exertion: a note on 'history' and methods. *Medicine and
941 Science in Sports and Exercise*. 1973;5(2):90-93.
- 942 32. Brouns F, Bjorck I, Frayn K, Gibbs A, Lang V, Slama G, Wolever T.
943 Glycaemic index methodology. *Nutrition Research Reviews*.
944 2005;18(1):145-171.
- 945 33. Gonzalez JT, Fuchs CJ, Smith FE, Thelwall PE, Taylor R, Stevenson EJ,
946 Trenell MI, Cermak NM, Van Loon LJ. Ingestion of glucose or sucrose
947 prevents liver but not muscle glycogen depletion during prolonged
948 endurance-type exercise in trained cyclists. *American Journal of Physiology-
949 Endocrinology and Metabolism*. 2015;309(12):1032-1039.
- 950 34. Fletcher G, Eves FF, Glover EI, Robinson SL, Vernooij CA, Thompson JL,
951 Wallis GA. Dietary intake is independently associated with the maximal
952 capacity for fat oxidation during exercise. *Am J Clin Nutr*. 2017;105(4):864-
953 872.
- 954 35. Edinburg R, Hengist A, Smith HA, Betts JA, Thompson D, Walhin J-P,
955 Gonzalez JT. Prior exercise alters the difference between arterialised and
956 venous glycaemia: implications for blood sampling procedures. *British
957 Journal of Nutrition*. 2017;117(10):1414-1421.
- 958 36. Passonneau J, Lauderdale V. A comparison of three methods of glycogen
959 measurement in tissues. *Analytical Biochemistry*. 1974;60(2):405-412.
- 960 37. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using
961 real-time quantitative PCR and the 2- $\Delta\Delta$ CT method. *methods*.
962 2001;25(4):402-408.
- 963 38. Satoh S, Nishimura H, Clark AE, Kozka IJ, Vannucci SJ, Simpson IA, Quon
964 MJ, Cushman SW, Holman GD. Use of bismannose photolabel to elucidate
965 insulin-regulated GLUT4 subcellular trafficking kinetics in rat adipose cells.
966 Evidence that exocytosis is a critical site of hormone action. *Journal of
967 Biological Chemistry*. 1993;268(24):17820-17829.

- 968 39. Hoshino S, Sakamoto K, Vassilopoulos S, Camus SM, Griffin CA, Esk C,
969 Torres JA, Ohkoshi N, Ishii A, Tamaoka A. The CHC22 clathrin-GLUT4
970 transport pathway contributes to skeletal muscle regeneration. *PloS one*.
971 2013;8(10):e77787.
- 972 40. Näthke IS, Heuser J, Lupas A, Stock J, Turck CW, Brodsky FM. Folding and
973 trimerization of clathrin subunits at the triskelion hub. *Cell*. 1992;68(5):899-
974 910.
- 975 41. Kjøbsted R, Hingst JR, Fentz J, Foretz M, Sanz MN, Pehmøller C, Shum M,
976 Marette A, Mounier R, Treebak JT, Wojtaszewski JFP, Viollet B, Lantier L.
977 AMPK in skeletal muscle function and metabolism. *FASEB J*.
978 2018;32(4):1741-1777.
- 979 42. Miklosz A, Chabowski A, Zendzian-Piotrowska M, Gorski J. Effects of
980 hyperthyroidism on lipid content and composition in oxidative and glycolytic
981 muscles in rats. *J Physiol Pharmacol*. 2012;63:403-410.
- 982 43. Miklosz A, Łukaszuk B, Żendzian-Piotrowska M, Kurek K, Chabowski A. The
983 effects of AS160 modulation on fatty acid transporters expression and lipid
984 profile in L6 myotubes. *Cellular Physiology and Biochemistry*.
985 2016;38(1):267-282.
- 986 44. Compher C, Frankenfield D, Keim N, Roth-Yousey L, Group EAW. Best
987 practice methods to apply to measurement of resting metabolic rate in
988 adults: a systematic review. *Journal of the American Dietetic Association*.
989 2006;106(6):881-903.
- 990 45. Frayn K. Calculation of substrate oxidation rates in vivo from gaseous
991 exchange. *Journal of Applied Physiology*. 1983;55(2):628-634.
- 992 46. Jeukendrup A, Wallis G. Measurement of substrate oxidation during
993 exercise by means of gas exchange measurements. *International Journal of*
994 *Sports Medicine*. 2005;26(1):28-37.
- 995 47. Thompson D, Batterham AM, Bock S, Robson C, Stokes K. Assessment of
996 low-to-moderate intensity physical activity thermogenesis in young adults
997 using synchronized heart rate and accelerometry with branched-equation
998 modeling. *The Journal of Nutrition*. 2006;136(4):1037-1042.
- 999 48. Villars C, Bergouignan A, Dugas J, Antoun E, Schoeller DA, Roth H,
1000 Maingon A-C, Lefai E, Blanc S, Simon C. Validity of combining heart rate
1001 and uniaxial acceleration to measure free-living physical activity energy
1002 expenditure in young men. *Journal of applied physiology*.
1003 2012;113(11):1763-1771.
- 1004 49. Brage S, Westgate K, Franks PW, Stegle O, Wright A, Ekelund U, Wareham
1005 NJ. Estimation of free-living energy expenditure by heart rate and movement
1006 sensing: a doubly-labelled water study. *PloS one*. 2015;10(9):Epub:
1007 <https://doi.org/10.1371/journal.pone.0137206>.
- 1008 50. Mari A, Pacini G, Brazzale AR, Ahrén B. Comparative evaluation of simple
1009 insulin sensitivity methods based on the oral glucose tolerance test.
1010 *Diabetologia*. 2005;48(4):748-751.
- 1011 51. Edinburgh R, Bradley H, Abdullah N, Robinson S, Chrzanowski-Smith O,
1012 Walhin J, Joanisse S, Manolopoulos K, Philp A, Hengist A, Chabowski A,

- 1013 Brodsky F, Koumanov F, Betts J, Thompson D, Wallis G, Gonzalez J.
1014 Dataset for "Lipid metabolism links nutrient-exercise timing to insulin
1015 sensitivity in overweight men". *University of Bath Research Data Archive*
1016 <https://doi.org/1015125/BATH-00672>. 2019.
- 1017 52. Perry CG, Lally J, Holloway GP, Heigenhauser GJ, Bonen A, Spriet LL.
1018 Repeated transient mRNA bursts precede increases in transcriptional and
1019 mitochondrial proteins during training in human skeletal muscle. *The Journal*
1020 *of Physiology*. 2010;588(23):4795-4810.
- 1021 53. Ehrenborg E, Krook A. Regulation of skeletal muscle physiology and
1022 metabolism by peroxisome proliferator-activated receptor δ .
1023 *Pharmacological Reviews*. 2009;61(3):373-393.
- 1024 54. Russell AP, Hesselink MK, Lo SK, Schrauwen P. Regulation of metabolic
1025 transcriptional co-activators and transcription factors with acute exercise.
1026 *The FASEB journal*. 2005;19(8):986-988.
- 1027 55. Polonsky KS, Rubenstein AH. C-peptide as a measure of the secretion and
1028 hepatic extraction of insulin: pitfalls and limitations. *Diabetes*.
1029 1984;33(5):486-494.
- 1030 56. Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ. A model-based method for
1031 assessing insulin sensitivity from the oral glucose tolerance test. *Diabetes*
1032 *Care*. 2001;24(3):539-548.
- 1033 57. Vessby B, Tengblad S, Lithell H. Insulin sensitivity is related to the fatty acid
1034 composition of serum lipids and skeletal muscle phospholipids in 70-year-
1035 old men. *Diabetologia*. 1994;37(10):1044-1050.
- 1036 58. Helge JW, Wu BJ, Willer M, Daugaard JR, Storlien LH, Kiens B. Training
1037 affects muscle phospholipid fatty acid composition in humans. *Journal of*
1038 *Applied Physiology*. 2001;90(2):670-677.
- 1039 59. Bergouignan A, Trudel G, Simon C, Chopard A, Schoeller DA, Momken I,
1040 Votruba SB, Desage M, Burdige GC, Gauquelin-Koch G. Physical inactivity
1041 differentially alters dietary oleate and palmitate trafficking. *Diabetes*.
1042 2009;58(2):367-376.
- 1043 60. Lefai E, Blanc S, Momken I, Antoun E, Chery I, Zahariev A, Gabert L,
1044 Bergouignan A, Simon C. Exercise training improves fat metabolism
1045 independent of total energy expenditure in sedentary overweight men, but
1046 does not restore lean metabolic phenotype. *International Journal Of Obesity*.
1047 2017;41(1):1728-1736.
- 1048 61. Handschin C, Spiegelman BM. Peroxisome Proliferator-Activated Receptor
1049 γ Coactivator 1 Coactivators, Energy Homeostasis, and Metabolism.
1050 *Endocrine Reviews*. 2006;27(7):728-735.
- 1051 62. Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, Mootha V, Troy
1052 A, Cinti S, Lowell B, Scarpulla RC. Mechanisms controlling mitochondrial
1053 biogenesis and respiration through the thermogenic coactivator PGC-1. *Cell*.
1054 1999;98(1):115-124.
- 1055 63. Ojuka EO, Jones TE, Nolte LA, Chen M, Wamhoff BR, Sturek M, Holloszy
1056 JO. Regulation of GLUT4 biogenesis in muscle: evidence for involvement of

- 1057 AMPK and Ca²⁺. *American Journal of Physiology-Endocrinology and*
1058 *Metabolism*. 2002;282(5):1008-1013.
- 1059 64. Frøsig C, Jørgensen SB, Hardie DG, Richter EA, Wojtaszewski JF. 5'-AMP-
1060 activated protein kinase activity and protein expression are regulated by
1061 endurance training in human skeletal muscle. *American Journal of*
1062 *Physiology-Endocrinology and Metabolism*. 2004;286(3):411-417.
- 1063 65. Friedrichsen M, Mortensen B, Pehmøller C, Birk JB, Wojtaszewski JF.
1064 Exercise-induced AMPK activity in skeletal muscle: role in glucose uptake
1065 and insulin sensitivity. *Molecular and Cellular Endocrinology*.
1066 2013;366(2):204-214.
- 1067 66. Richter EA, Hargreaves M. Exercise, GLUT4, and skeletal muscle glucose
1068 uptake. *Physiological Reviews*. 2013;93(3):993-1017.
- 1069 67. Leturque A, Loizeau M, Vaulont S, Salminen M, Girard J. Improvement of
1070 Insulin Action in Diabetic Transgenic Mice Selectively Overexpressing
1071 GLUT4 in Skeletal Muscle. *Diabetes*. 1996;45(1):23-27.
- 1072 68. Watt MJ, Steinberg GR, Chen ZP, Kemp BE, Febbraio MA. Fatty acids
1073 stimulate AMPK-activated protein kinase and enhance fatty acid oxidation in
1074 L6 myotubes. *Journal of Physiology*. 2006;574(1):139-147.
- 1075 69. Wojtaszewski JF, Birk JB, Frøsig C, Holten M, Pilegaard H, Dela F. 5'AMP
1076 activated protein kinase expression in human skeletal muscle: effects of
1077 strength training and type 2 diabetes. *J Physiol*. 2005;564(Pt 2):563-573.
- 1078 70. Hansen PA, Nolte LA, Chen MM, Holloszy JO. Increased GLUT-4
1079 translocation mediates enhanced insulin sensitivity of muscle glucose
1080 transport after exercise. *Journal of Applied Physiology*. 1998;85(4):1218-
1081 1222.
- 1082 71. Fisher JS, Gao J, Han D-H, Holloszy JO, Nolte LA. Activation of AMP kinase
1083 enhances sensitivity of muscle glucose transport to insulin. *American*
1084 *Journal of Physiology-Endocrinology and Metabolism*. 2002;282(1):E18-
1085 E23.
- 1086 72. Vassilopoulos S, Esk C, Hoshino S, Funke BH, Chen C-Y, Plocik AM,
1087 Wright WE, Kucherlapati R, Brodsky FM. A role for the CHC22 clathrin
1088 heavy-chain isoform in human glucose metabolism. *Science*.
1089 2009;324(5931):1192-1196.
- 1090 73. Fumagalli M, Camus SM, Diekmann Y, Burke A, Camus MD, Norman PJ,
1091 Joseph AP, Abi-Rache L, Benazzo A, Rasteiro R, Mathieson I, Topf M,
1092 Parham P, Thomas MG, Brodsky FM. Genetic diversity of CHC22 clathrin
1093 impacts its function in glucose metabolism. *eLife*. 2019;8.
- 1094 74. Dannhauser PN, Camus SM, Sakamoto K, Sadacca LA, Torres JA, Camus
1095 MD, Briant K, Vassilopoulos S, Rothnie A, Smith CJ, Brodsky FM. CHC22
1096 and CHC17 clathrins have distinct biochemical properties and display
1097 differential regulation and function. *The Journal of biological chemistry*.
1098 2017;292(51):20834-20844.
- 1099 75. Weijers R. Lipid composition of cell membranes and its relevance in type 2
1100 diabetes mellitus. *Current diabetes reviews*. 2012;8(5):390-400.

- 1101 76. Apostolopoulou M, Strassburger K, Herder C, Knebel B, Kotzka J,
1102 Szendroedi J, Roden M. Metabolic flexibility and oxidative capacity
1103 independently associate with insulin sensitivity in individuals with newly
1104 diagnosed type 2 diabetes. *Diabetologia*. 2016;59(10):2203-2207.
- 1105 77. Chowdhury EA, Richardson JD, Holman GD, Tsintzas K, Thompson D,
1106 Betts JA. The causal role of breakfast in energy balance and health: a
1107 randomized controlled trial in obese adults. *The American Journal of Clinical*
1108 *Nutrition*. 2016;103(3):747-756.
1109

Table 1. Participant characteristics

	Study 1		Study 2 - Training Study		<i>p</i> -value (Training study)
	Acute Study	CON	BR-EX	EX-BR	
<i>n</i>	12	9	12	9	
Body Mass (kg)	95.1 (13.6)	101.1 (19.5)	95.2 (12.4)	98.0 (18.8)	0.73
BMI (kg·m ⁻²)	30.2 (3.5)	31.8 (5.8)	30.3 (3.9)	30.8 (4.1)	0.75
Waist Circumference (cm)	105.7 (11.6)	107.7 (14.8)	103.9 (8.9)	104.7 (11.6)	0.63
Hip Circumference (cm)	110.9 (6.5)	110.8 (8.4)	111.4 (7.1)	111.6 (8.5)	0.32
Waist-to-Hip Ratio	0.95 (0.08)	0.97 (0.06)	0.93 (0.04)	0.94 (0.05)	0.31
$\dot{V}O_2$ peak (ml·kg ⁻¹ ·min ⁻¹)	29.1 (5.3)	32.6 (7.7)	34.3 (5.6)	32.4 (4.0)	0.71
PPO (W)	156 (39)	204 (47)	208 (26)	203 (22)	0.73
Physical Activity Level	-	1.71 (0.16)	1.68 (0.16)	1.68 (0.11)	0.90

Data are means (SD) for men classified as overweight or obese. BMI = Body Mass Index; $\dot{V}O_2$ peak = peak oxygen uptake; PPO = peak power output; CON = control; BR-EX = breakfast-exercise; EX-BR = exercise-breakfast.

1111 **Table 2.** List of genes analyzed for mRNA expression

Gene	Qiagen catalogue number	Refseq#
<i>CD36</i>	Cat#PPH01356A	NM_000072
<i>SLC27A1</i>	Cat#PPH17902A	NM_198580
<i>SLC27A4</i>	Cat#PPH00471A	NM_005094
<i>FABP3</i>	Cat#PPH02460C	NM_004102
<i>FABP4</i>	Cat#PPH02382F	NM_001442
<i>ACSL1</i>	Cat#PPH19272A	NM_001995
<i>ACSL6</i>	Cat#PPH08013A	NM_001009185
<i>CPT1B</i>	Cat#PPH20905B	NM_001145134
<i>CPT2</i>	Cat#PPH15572A	NM_000098
<i>ACACA</i>	Cat#PPH02316A	NM_000664
<i>ACACB</i>	Cat#PPH02301A	NM_001093
<i>MLYCD</i>	Cat#PPH12795A	NM_012213
<i>HADHA</i>	Cat#PPH10000B	NM_000182
<i>GPAM</i>	Cat#PPH06361A	NM_001244949
<i>DGAT1</i>	Cat#PPH23420F	NM_012079
<i>PNPLA2</i>	Cat#PPH11403B	NM_020376
<i>LIPE</i>	Cat#PPH02383A	NM_005357
<i>PDK4</i>	Cat#PPH07615A	NM_002612
<i>PDK2</i>	Cat#PPH00810A	NM_001199898
<i>GYG1</i>	Cat#PPH13614A	NM_001184720
<i>GYS1</i>	Cat#PPH00988C	NM_001161587
<i>PRKAA1</i>	Cat#PPH00043B	NM_206907
<i>PRKAA2</i>	Cat#PPH15207A	NM_006252
<i>PRKAB2</i>	Cat#PPH09415B	NM_005399
<i>PRKAG1</i>	Cat#PPH07190A	NM_001206709
<i>PPARGC1A</i>	Cat#PPH00461F	NM_013261
<i>PPARA</i>	Cat#PPH01281B	NM_001001928
<i>PPARD</i>	Cat#PPH00455A	NM_001171818
<i>UCP3</i>	Cat#PPH06066A	NM_003356
<i>IL6</i>	Cat#PPH00560C	NM_000600
<i>SLC2A4</i>	Cat#PPH02326A	NM_001042
<i>IRS1</i>	Cat#PPH02328A	NM_005544
<i>IRS2</i>	Cat#PPH02297A	NM_003749
<i>AKT2</i>	Cat#PPH00289F	NM_001243027

1112

1113

Table 3. Postprandial plasma metabolite concentrations for the control (CON; $n=9$), breakfast-exercise (BR-EX; $n=12$) and exercise-breakfast (EX-BR; $n=9$) groups.

	Pre-intervention	Post-intervention	<i>p</i> -value (within-group change)
CON glucose AUC (mmol·L ⁻¹)	8.20 (1.36)	8.43 (0.89)	0.69
BR-EX glucose AUC (mmol·L ⁻¹)	8.26 (0.90)	8.34 (1.35)	0.78
EX-BR glucose AUC (mmol·L ⁻¹)	8.52 (1.05)	8.14 (1.03)	0.27
CON insulin AUC (pmol·L ⁻¹)	385 (221)	514 (382)	0.08
BR-EX insulin AUC (pmol·L ⁻¹)	268 (109)	303 (135)	0.16
EX-BR insulin AUC (pmol·L ⁻¹)	458 (441)	355 (254)	0.21
CON C-peptide AUC (ng·mL ⁻¹)	6.59 (2.57)	7.32 (3.11)	0.18
BR-EX C-peptide AUC (ng·mL ⁻¹)	5.25 (1.72)	5.54 (1.87)	0.34
EX-BR C-peptide AUC (ng·mL ⁻¹)	6.81 (4.40)	6.03 (3.45)	0.28
CON NEFA AUC (mmol·L ⁻¹)	0.17 (0.07)	0.19 (0.07)	0.52
BR-EX NEFA AUC (mmol·L ⁻¹)	0.20 (0.08)	0.16 (0.06)	0.08
EX-BR NEFA AUC (mmol·L ⁻¹)	0.14 (0.03)	0.13 (0.04)	0.48
CON OGIS (mL·min ⁻¹ ·m ⁻²)	401 (39)	372 (63)	0.19
BR-EX OGIS (mL·min ⁻¹ ·m ⁻²)	403 (31)	380 (34)	0.06
EX-BR OGIS (mL·min ⁻¹ ·m ⁻²)	374 (56)	399 (42)	0.08

Data are means and (SD). Abbreviations: NEFA = non-esterified fatty acid, OGIS = oral glucose insulin sensitivity, AUC = time-averaged area under the curve for the OGTT (120 min).

Table 4. Fasting plasma metabolite concentrations for the control (CON; $n=9$), breakfast-exercise (BR-EX; $n=12$) and exercise-breakfast (EX-BR; $n=9$) groups.

	Pre-intervention	Post-intervention	Δ from pre-intervention	time x group interaction
CON glucose (mmol·L ⁻¹)	5.39 (0.49)	5.57 (0.66)	0.17 (-0.32, 0.66)	F=1.413 $p=0.26$
BR-EX glucose (mmol·L ⁻¹)	5.48 (0.33)	5.60 (0.47)	0.12 (-0.30, 0.54)	
EX-BR glucose (mmol·L ⁻¹)	5.72 (0.71)	5.46 (0.72)	-0.27 (-0.67, 0.13)	
CON insulin (pmol·L ⁻¹)	95 (121)	81 (63)	-14 (-7, 8)	F=0.327 $p=0.72$
BR-EX insulin (pmol·L ⁻¹)	43 (23)	43 (24)	0 (-14, 15)	
EX-BR insulin (pmol·L ⁻¹)	49 (43)	47 (35)	-2 (-20, 14)	
CON HOMA-IR (au)	0.35 (0.04)	0.34 (0.03)	-0.01 (-0.02, 0.00)	F=0.458 $p=0.40$
BR-EX HOMA-IR (au)	0.37 (0.03)	0.37 (0.04)	0.00 (-0.01, 0.01)	
EX-BR HOMA-IR (au)	0.37 (0.04)	0.37 (0.04)	0.01 (-0.02, 0.04)	
CON NEFA (mmol·L ⁻¹)	0.36 (0.16)	0.39 (0.11)	0.03 (-0.10, 0.15)	F=1.021 $p=0.37$
BR-EX NEFA (mmol·L ⁻¹)	0.44 (0.15)	0.39 (0.10)	-0.05 (-0.11, 0.15)	
EX-BR NEFA (mmol·L ⁻¹)	0.34 (0.09)	0.32 (0.10)	-0.02 (-0.09, 0.05)	
CON TAG (mmol·L ⁻¹)	1.59 (0.77)	2.05 (0.70)	0.46 (-0.06, 0.98)	F= 5.967 $p<0.01$
BR-EX TAG (mmol·L ⁻¹)	1.34 (0.84)	1.11 (0.42)	-0.24 (-0.55, 0.76) a	
EX-BR TAG (mmol·L ⁻¹)	1.10 (0.31)	0.88 (0.36)	-0.22 (-0.41, -0.03) b	
CON cholesterol (mmol·L ⁻¹)	4.41 (1.23)	4.59 (1.36)	0.19 (-0.74, 1.12)	F=1.707 $p=0.20$
BR-EX cholesterol (mmol·L ⁻¹)	3.77 (1.34)	3.72 (1.21)	-0.05 (-0.41, 0.30)	
EX-BR cholesterol (mmol·L ⁻¹)	3.74 (0.82)	3.24 (0.92)	-0.51 (-0.95, -0.07)	
CON HDL cholesterol (mmol·L ⁻¹)	0.84 (0.17)	0.86 (0.20)	0.02 (-0.14, 0.18)	F=1.634 $p=0.21$
BR-EX HDL cholesterol (mmol·L ⁻¹)	0.82 (0.31)	0.84 (0.33)	0.02 (-0.05, 0.10)	
EX-BR HDL cholesterol (mmol·L ⁻¹)	0.90 (0.23)	0.81 (0.26)	-0.09 (-0.19, 0.01)	
CON LDL cholesterol (mmol·L ⁻¹)	3.36 (1.33)	3.56 (1.36)	0.20 (-0.50, 0.89)	F=2.110 $p=0.14$
BR-EX LDL cholesterol (mmol·L ⁻¹)	2.71 (0.97)	2.70 (0.99)	-0.01 (-0.31, 0.28)	
EX-BR LDL cholesterol (mmol·L ⁻¹)	2.72 (0.57)	2.31 (0.58)	-0.41 (-0.80, -0.02)	

Data are means and (SD) except for change scores which are means and (95% CI). Abbreviations: HOMA-IR = the homeostatic model of insulin resistance, NEFA = non-esterified fatty acid, TAG = triglyceride, HDL = high density lipoprotein, LDL = low density lipoprotein. (a) = difference in change from pre- to post-intervention for CON *versus* BR-EX and (b) CON *versus* EX-BR with $p<0.05$.

Table 5. Components of daily energy intake and daily energy expenditure pre- and post-intervention for the control (CON; n=9 [except for PAEE where n=8]), breakfast before exercise (BR-EX; n=12 [except for PAEE where n=10]) and exercise before breakfast (EX-BR; n=9) groups.

	Pre-intervention	Post-intervention	Δ from pre-intervention	time x group interaction
CON CHO intake (kcal·d ⁻¹)	1180 (357)	1424 (600)	244 (-29, 517)	F=0.977 p=0.39
BR-EX CHO intake (kcal·d ⁻¹)	1171 (317)	1272 (220)	101 (-51, 252)	
EX-BR CHO intake (kcal·d ⁻¹)	1133 (307)	1214 (234)	81 (-91, 252)	
CON FAT intake (kcal·d ⁻¹)	1148 (326)	1045 (311)	-104 (-257, 49)	F=0.347 p=0.71
BR-EX FAT intake (kcal·d ⁻¹)	1132 (307)	1091 (238)	-41 (-156, 75)	
EX-BR FAT intake (kcal·d ⁻¹)	987 (320)	882 (172)	-105 (-289, 79)	
CON PRO intake (kcal·d ⁻¹)	429 (97)	376 (89)	-52 (-89, 15)	F=1.517 p=0.24
BR-EX PRO intake (kcal·d ⁻¹)	511 (122)	446 (59)	-65 (-118, -11)	
EX-BR PRO intake (kcal·d ⁻¹)	406 (97)	399 (117)	-7 (-75, 62)	
CON ALC intake (kcal·d ⁻¹)	72 (95)	75 (154)	3 (-145, 152)	F=1.115 p=0.34
BR-EX ALC intake (kcal·d ⁻¹)	111 (118)	69 (72)	-42, (-101, 17)	
EX-BR ALC intake (kcal·d ⁻¹)	185 (168)	90 (131)	-94 (-191, 2)	
CON RMR (kcal·d ⁻¹)	1997 (225)	2021 (232)	24 (-56, 104)	F=1.791 p=0.19
BR-EX RMR (kcal·d ⁻¹)	1964 (167)	2074 (208)	110 (45, 174)	
EX-BR RMR (kcal·d ⁻¹)	1899 (228)	1967 (194)	68 (-13, 148)	
CON TEF (kcal·d ⁻¹)	283 (61)	292 (85)	9 (-29, 48)	F=0.982 p= 0.38
BR-EX TEF (kcal·d ⁻¹)	292 (50)	288 (42)	-4 (-19, 10)	
EX-BR TEF (kcal·d ⁻¹)	271 (55)	258 (44)	-13 (-29, 4)	
CON PAEE (kcal·d ⁻¹)	1144 (298)	1077 (327)	-67 (-215, 81)	F=7.044 p<0.01
BR-EX PAEE (kcal·d ⁻¹)	986 (264)	1190 (343)	204 (56, 352) a	
EX-BR PAEE (kcal·d ⁻¹)	1006 (147)	1357 (324)	351 (126, 576) b	

Data are means and (SD) except for change scores which are means and (95% CI). Abbreviations: CHO = carbohydrate, PRO = protein, ALC = alcohol, RMR = resting metabolic rate, TEF = thermic effect of feeding, PAEE = physical activity energy expenditure. (a) = difference in change from pre- to post-intervention for CON *versus* BR-EX and (b) CON *versus* EX-BR with p<0.05.


Table 6. Skeletal muscle phospholipid composition in the control (CON; $n=6$), breakfast-exercise (BR-EX; $n=8$) and exercise-breakfast (EX-BR; $n=5$) groups.

	Pre-intervention	Post-intervention	time x group interaction
CON 14:0 (% of total)	1.3 (0.5)	1.0 (0.3)	F=0.493 $p=0.62$
BR-EX 14:0 (% of total)	0.8 (0.1)	0.7 (0.1)	
EX-BR 14:0 (% of total)	0.8 (0.4)	0.7 (0.1)	
CON 16:0 (% of total)	24.8 (2.3)	24.3 (1.0)	F=1.537 $p=0.25$
BR-EX 16:0 (% of total)	22.4 (0.6)	21.7 (1.2)	
EX-BR 16:0 (% of total)	19.5 (1.5)	17.9 (1.4)	
CON 18:0 (% of total)	14.2 (0.3)	14.2 (0.5)	F=7.205 $p<0.01$
BR-EX 18:0 (% of total)	14.6 (0.4)	15.2 (0.6)	
EX-BR 18:0 (% of total)	11.9 (0.8)	13.0 (0.8) b	
CON 20:0 (% of total)	0.13 (0.05)	0.09 (0.02)	F=1.141 $p=0.34$
BR-EX 20:0 (% of total)	0.08 (0.02)	0.08 (0.04)	
EX-BR 20:0 (% of total)	0.10 (0.04)	0.10 (0.07)	
CON 22:0 (% of total)	0.21 (0.07)	0.20 (0.02)	F=0.666 $p=0.53$
BR-EX 22:0 (% of total)	0.20 (0.04)	0.19 (0.04)	
EX-BR 22:0 (% of total)	0.20 (0.05)	0.23 (0.10)	
CON 24:0 (% of total)	0.15 (0.07)	0.14 (0.04)	F=0.108 $p=0.90$
BR-EX 24:0 (% of total)	0.12 (0.08)	0.11 (0.06)	
EX-BR 24:0 (% of total)	0.16 (0.08)	0.13 (0.06)	
CON 16:1 (% of total)	0.82 (0.34)	0.70 (0.19)	F=1.254 $p=0.31$
BR-EX 16:1 (% of total)	0.66 (0.12)	0.75 (0.26)	
EX-BR 16:1 (% of total)	0.66 (0.15)	0.62 (0.17)	
CON 18:1n9c (% of total)	7.9 (3.0)	7.1 (1.5)	F=2.970 $p=0.08$
BR-EX 18:1n9c (% of total)	6.3 (0.6)	6.8 (0.6)	
EX-BR 18:1n9c (% of total)	6.6 (1.3)	6.6 (0.9)	
CON 18:2n6c (% of total)	33.6 (5.0)	34.5 (4.1)	

BR-EX 18:2n6c (% of total)	37.2 (2.2)	37.7 (2.5)	F=0.250 $p=0.78$
EX-BR 18:2n6c (% of total)	29.2 (3.3)	30.5 (0.8)	
CON C18n3 (% of total)	0.23 (0.06)	0.21 (0.05)	F=1.842 $p=0.19$
BR-EX C18n3 (% of total)	0.25 (0.05)	0.29 (0.04)	
EX-BR C18n3 (% of total)	0.22 (0.03)	0.26 (0.02)	
CON 20:4n6 (% of total)	14.4 (0.8)	15.0 (1.8)	F=1.862 $p=0.19$
BR-EX 20:4n6 (% of total)	14.9 (1.8)	14.0 (1.4)	
EX-BR 20:4n6 (% of total)	11.9 (1.3)	11.0 (1.7)	
CON 20:5n3 (% of total)	0.66 (0.21)	0.71 (0.18)	F=0.245 $p=0.79$
BR-EX 20:5n3 (% of total)	0.71 (0.12)	0.73 (0.12)	
EX-BR 20:5n3 (% of total)	0.64 (0.18)	0.69 (0.18)	
CON 22:6n3 (% of total)	1.5 (0.4)	1.6 (0.5)	F=0.077 $p=0.93$
BR-EX 22:6n3 (% of total)	1.6 (0.2)	1.6 (0.2)	
EX-BR 22:6n3 (% of total)	1.3 (0.5)	1.4 (0.3)	
CON 24:1 (% of total)	0.13 (0.08)	0.13 (0.05)	F=0.021 $p=0.98$
BR-EX 24:1 (% of total)	0.10 (0.03)	0.10 (0.04)	
EX-BR 24:1 (% of total)	0.14 (0.09)	0.13 (0.08)	


Data are means and (SD). (b) = difference in change from pre- to post-intervention for CON *versus* EX-BR.

1117 **Figures**



1118
1119


Figure 1. Protocol schematic for the training study.



1120
1121
1122
1123


Figure 2. Plasma glucose (A), serum insulin (B), plasma glycerol (C) and plasma NEFA (D) concentrations and whole-body carbohydrate (E) and fat (F) utilization rates. Muscle was sampled pre- and immediately post-exercise (*vastus lateralis*) to

1124 assess mixed-muscle glycogen (**G**) and fiber-type specific intramuscular lipid (IMTG)
1125 utilization (**H & I**). Panel **J** is representative images from IMTG staining where IMTG
1126 (stained green) in combination with dystrophin (to identify the cell border and stained
1127 red) is shown from skeletal muscle samples of a representative participant for the
1128 breakfast-exercise and exercise-breakfast trials. White I shows type 1 fibers and all
1129 other fibers are assumed to be type II. Yellow bars are scale (50 μm). All data are
1130 presented as means \pm 95% CI. For panels **A-F** $n=12$ men classified as overweight
1131 or obese, for panels **G, H and I** $n=9$. ^adifference between PRE *versus* POST
1132 exercise; ^bdifference between BREAKFAST-EXERCISE *versus* EXERCISE-
1133 BREAKFAST ($p < 0.05$).



1134
1135
1136
1137
1138
1139
1140

Figure 3. Skeletal muscle mRNA expression responses to a single bout of exercise before *versus* after nutrient provision (in the form of breakfast) in overweight men. $n=8$. Muscle was sample pre- and at 3 h post-exercise (*vastus lateralis*) to assess the intramuscular gene expression responses to exercise. ^aeffect of exercise; ^b difference between BREAKFAST-EXERCISE *versus* EXERCISE-BREAKFAST ($p < 0.05$).



1141

1142

1143

1144


1145

1146

Figure 4. Whole-body lipid utilization during every exercise session in a 6-week training intervention (**A**), the change in the plasma glucose AUC (**B**), the change in the plasma insulin AUC (**C**), the change in the oral glucose insulin sensitivity index (OGIS; **D**) and the change in the postprandial plasma C-peptide: insulin ratio (**E**) in control (no-exercise), breakfast-exercise and exercise-breakfast groups. Panel **F**

1147 shows the Pearson correlation between changes in the OGIS index and cumulative
1148 lipid utilization throughout the exercise training intervention. All data are presented
1149 as means \pm 95% CI. For control $n = 9$, for breakfast-exercise $n = 12$ and for exercise-
1150 breakfast $n = 9$ men classified as overweight or obese. The shaded grey area
1151 represents the 95% confidence bands for the regression line. ^adifference between
1152 CONTROL *versus* EXERCISE-BREAKFAST; ^bdifference between BREAKFAST-
1153 EXERCISE *versus* EXERCISE-BREAKFAST ($p < 0.05$).

1154



1155

1156

1157

1158

1159

1160


1161

1162

1163


1164

Figure 5. Energy expenditure (A), the respiratory exchange ratio (B) and whole-body carbohydrate utilisation rates (C) during every exercise session in a 6-week training intervention and a Pearson correlation between cumulative energy expenditure throughout the exercise training intervention with the changes in oral glucose insulin sensitivity (the OGIS index) with exercise before *versus* after nutrient intake (D). All data are presented as means \pm 95% CI. For control $n = 9$, for breakfast-exercise $n = 12$ and for exercise-breakfast $n = 9$ men classified as overweight or obese. The shaded grey area represents the 95% confidence bands for the regression line.




1165
1166
1167
1168
1169
1170
1171
1172
1173

Figure 6. Body mass (**A**), the waist-to-hip ratio (**B**), whole-body oxidative capacity (VO_{2peak} ; **C**) and peak fat utilization rates during an incremental exercise test (**D**) at baseline, week 3 and week 6 of an intervention in control (no-exercise), breakfast-exercise and exercise-breakfast groups. All data are presented as means \pm 95% CI. For control $n = 9$, for breakfast-exercise $n = 12$ and for exercise-breakfast $n = 9$ men classified as overweight or obese ^adifference between CONTROL versus BREAKFAST-EXERCISE; ^bdifference between CONTROL versus EXERCISE-BREAKFAST ($p < 0.05$).



1174
1175
1176
1177
1178
1179
1180
1181
1182

Figure 7. Pre-to-post intervention changes in the sum of all changes in the fatty acid content of phospholipid species (A) and a Pearson correlation between postprandial insulinemia with the change in the proportion of saturated fatty acids in skeletal muscle phospholipids (B). All data are presented as means \pm 95% CI. For control $n = 6$, for breakfast-exercise $n = 9$ and for exercise-breakfast $n = 5$ men classified as overweight or obese. The shaded area represents the 95% confidence bands for the regression line. ^bdifference between BREAKFAST-EXERCISE versus EXERCISE-BREAKFAST ($p < 0.05$).



1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194

Figure 8. Pre-to-post intervention changes in the levels of energy-sensing proteins and proteins involved in insulin-sensitive GLUT4 trafficking in skeletal muscle (**A** and **B**). Representative immunoblots are shown (**C**) for each protein (including those reported in text but not shown in this figure) from the same representative participant as well as the loading controls used. All data are presented as means \pm 95% CI and the dotted horizontal line represents the baseline (pre-intervention) values. For control $n = 6$, for breakfast-exercise $n = 9$ and for exercise-breakfast $n = 5$ men classified as overweight or obese. ^adifference between CONTROL versus EXERCISE-BREAKFAST; ^bdifference between BREAKFAST-EXERCISE versus EXERCISE-BREAKFAST; ^cdifference between CONTROL versus BREAKFAST-EXERCISE ($p < 0.05$).